 
Document Type:  Study protocol  
Official Title:  A multi- center, pediatric phase III, non- controlled, open- label 
trial to evaluate the safety of BAY 94 9027 for prophylaxis and 
treatment of bleedings in previously Treated Patients aged 7- <12 
years  with severe hemophilia A  
Study ID: [REMOVED] 
Document D ate: 06-Apr-2023  
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global)
No. BAY 94-9027 / [ZIP_CODE]
06 APR 2023 Page: 1 of 69
Title Page
Protocol Title: 
A Phase 3, single-group treatment, open-label, study to evaluate the safety of BAY 94-9027
infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A
Protocol Number: [ZIP_CODE]
Protocol Version: 3.0
Amendment Number: 2
Amendment Scope: Global
Compound Number: Damoctocog alfa pegol (Jivi
®), BAY 94-9027
Short Title: A Phase 3 safety study of BAY 94-9027 in children 7 to <12 years 
of age with severe hemophilia A
Study Phase: 3
Acronym: Alfa-PROTECT
Sponsor Name: [CONTACT_266953]: Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, 
Switzerland
Regulatory Agency Identifier Number(s): EudraCT no.: 2021-004858-[ADDRESS_324801] no.: 2023-504388-18-00
Protocol Date: 06 APR 2023
Name: [CONTACT_1221]:
This is an electronically generated document that does not bear any sponsor signatures. The 
signature [CONTACT_8152]’s medically responsible person i s filed in the TMF and available on 
request.
Medical Monitor name [CONTACT_3669] [CONTACT_266918].
Confidential
The information provided in this document is strictly conf idential and is intended solely for the performance of the 
clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not
associated with the clinical investigation or its use for any other purpose without the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietar y names (®, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.[COMPANY_003] [COMPANY_003]
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  2 of 69 
 
Document History Table 
DOCUMENT HISTORY 
Document  Version  Date Comments (if applicable) 
Amendment 2 (Global) 3.0 06 APR 2023  
Amendment 1 (Global)  2.0 25 MAY 2022   
Clinical Study Protocol  1.0 17 SEP 2020  Version approved by [CONTACT_266919] 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  3 of 69 
 
Protocol Amendment Summary of Changes Table 
Amendment 2 (06 APR 2023) This amendment is considered to be substantial base d on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC and Article 2(2)(13) of the REGULATION (EU) No 536/2014 of the 
European Parliament and the Council of the European Union. 
Overall Rationale for the Amendment: Immunogenicity to the PEG moiety in Jivi is age related. Preliminary data from the initial 
patients dosed in this study indicate that when an immune response occurs, it is less severe in this 
age group than that typi[INVESTIGATOR_266893] 2-5 years of age. This reduced immune response has been characterized by [CONTACT_266920]-PEG antibodies (1:1 to 1:4) with 
mild to moderate reductions in FVIII recovery during EDs 2-4. Continued dosing with Jivi has 
demonstrated decreased levels of anti-PEG  antibodies and improved FVIII recovery.  
The original protocol specifies that local FVIII recovery measurements are performed at the 
clinical site based on the investigator's discretion or when there is suspi[INVESTIGATOR_266894]. 
To better protect study participants against the potential for a bleed related to lower-than-
expected FVIII levels, this amendment recommen ds routine local FVIII recovery measurements 
be performed at the clinical site for the first [ADDRESS_324802] the dose and dosing interval for the subsequent EDs.  
Section #  
and Name [CONTACT_266954]  
1.3  Schedule of Activities 
(SoA) Laboratory chemistry added 
at Visit [ADDRESS_324803] 4 E Ds updated  Change made for consistency throughout 
the protocol  
2.2  Background Description of 
immunogenicity to PEG and 
appropriate assessment of FVIII recovery levels in study participants added to section Age-appropriate frequency of FVIII 
recovery level  assessment will reduce the 
potential for bleeds and improve clinician management of study drug.
 
5.5  Criteria for Temporarily 
Delaying Study Intervention Condition added  Delay due to logistical reasons allowed to 
avoid  unnecessary rescreening 
procedures 
6.1  Study Intervention(s) 
Administered  Guidance added regarding 
appropriate dose when 
post-infusion FVIII levels 
are lower than expected Reduce the potential for bleeds in 
participants with low titer anti -PEG 
antibodies.  
6.[ADDRESS_324804] be managed at home without medical supervision.
 
[IP_ADDRESS]  Decreased Recovery Section added  Specific treatment and laboratory 
evaluations added for participants with lower than expected recovery
 after the 
first exposures 
8.3.[ADDRESS_324805] (AESI) Examples of Loss of 
Efficacy added Clarification added to ensure safe 
management of study participants 
 FVIII level and FVIII 
inhibitor testing guidance Specific guidance only applies to study 
participants that have discontinued study 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  4 of 69 
 
Section #  
and Name [CONTACT_266955]. 
10.2  Appendix 2: Clinical 
Laboratory Tests  Local laboratory testing 
guidance updated  Must be done as specified in the SoA, not 
just in cases where central laboratory 
results are not available. 
10.6  Appendix 6: Protocol 
Amendment History Section added Documentation of changes made in prior 
amendments 
 
Minor changes made throughout the document to correct typos, grammar, document headers, etc., 
are not individually summarized. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  5 of 69 
 
Table of Contents  
Title Page .................................................................................................................... ............... 1  
Document History Table ........................................................................................................ .. 2 
Protocol Amendment Summary of Changes Table ............................................................... 3  
Table of Contents ............................................................................................................. ........ 5  
Table of Tables ............................................................................................................... .......... 7  
1. Protocol Summary ............................................................................................................ 8  
1.1 Synopsis ...................................................................................................................... ..... 8  
1.2 Schema ........................................................................................................................ ..... 9  
1.3 Schedule of Activities (SoA) ......................................................................................... 10  
2. Introduction .................................................................................................................. ... 14  
2.1 Study Rationale .............................................................................................................. 14 
2.2 Background ....................................................................................................................  14 
2.3 Benefit/Risk Assessment ............................................................................................... 15  
2.3.1  Risk Assessment ......................................................................................................... 15  
2.3.2  Benefit Assessment .................................................................................................... 17  
2.3.3  Overall Benefit: Risk Conclusion ............................................................................... 18  
3. Objectives, Endpoints, and Estimands .......................................................................... 18  
4. Study Design .................................................................................................................. .. 21  
4.1 Overall Design ............................................................................................................... 21 
4.2 Scientific Rationale for Study Design ........................................................................... 21  
4.3 Justification for Dose ..................................................................................................... 21  
4.4 End of Study Definition ................................................................................................. 21  
5. Study Population ............................................................................................................. 22 
5.1 Inclusion Criteria ........................................................................................................... 22 
5.2 Exclusion Criteria .......................................................................................................... 2 2 
5.3 Lifestyle Considerations ................................................................................................ 23  
5.4 Screen Failures ...............................................................................................................  24 
5.5 Criteria for Temporarily Delaying Study Intervention .................................................. 24  
6. Study Intervention(s) and Concomitant Therapy ........................................................ 24  
6.1 Study Intervention(s) Administered ............................................................................... 24  
6.1.1  Medical Devices ......................................................................................................... 26  
6.2 Preparation, Handling, Storage, and Accountability ..................................................... 26  
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................... 26  
6.4 Study Intervention Compliance ..................................................................................... 27  
6.5 Dose Modification ......................................................................................................... 27  
6.6 Continued Access to Study Intervention After the End of the Study ............................ 27  
6.7 Treatment of Overdose .................................................................................................. 27  
6.8 Concomitant Therapy .................................................................................................... 27  
6.8.1  Rescue Medicine......................................................................................................... 28  
7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal
 .............................................................................................................................. ............. 28  
7.1 Discontinuation of Study Intervention ........................................................................... 28  
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... [ADDRESS_324806] to Follow Up .......................................................................................................... 29  
8. Study Assessments and Procedures ............................................................................... 30  
8.1 Efficacy Assessments .................................................................................................... 30  
8.1.1  BAY 94-9027 consumption ........................................................................................ 31  
8.1.2  Recording of Bleeding Epi[INVESTIGATOR_1841] ................................................................................ 31  
8.1.3  Clinical Outcome Assessments .................................................................................. 32  
[IP_ADDRESS]  Hemophilia Specific Quality of Life (Haemo-QoL) Questionnaire ........................ 32  
[IP_ADDRESS]  Patient/Caregiver Global Impression of Severity and Change ................................ 32  
8.2 Safety Assessments ........................................................................................................ 32  
8.2.1  Physical Examinations ................................................................................................ 33  
8.2.2  Vital Signs .................................................................................................................. 33 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  6 of 69 
 
8.2.3  Clinical Safety Laboratory Tests ................................................................................ 33  
[IP_ADDRESS]  Decreased recovery ................................................................................................. 34  
8.3 Adverse Events (AEs), Serious Adverse Events (SAEs) and Other Safety Reporting .. 34  
8.3.1  Time Period and Frequency for Collecting AE and SAE Information....................... 35  
8.3.2  Method of Detecting AEs and SAEs .......................................................................... 35  
8.3.3  Follow Up of AEs and SAEs ...................................................................................... 35  
8.3.4  Regulatory Reporting Requirements for SAEs .......................................................... 36  
8.3.5  Pregnancy ................................................................................................................... 3 6 
8.3.6  Cardiovascular and Death Events ............................................................................... 36  
8.3.7  Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or 
SAEs .......................................................................................................................... . [ADDRESS_324807] (AESI) ................................................................ 37  
[IP_ADDRESS]  Clinical guidance for hypersensitivity reactions requiring treatment ..................... 37  
[IP_ADDRESS]  Clinical guidance for loss of efficacy (LoE) ........................................................... 39  
[IP_ADDRESS]  Assessment of Severity of AESI ............................................................................. 39  
8.3.9  Other Important Events .............................................................................................. 40  
8.3.10  Medical Device Deficiencies ...................................................................................... 41  
8.4 Pharmacokinetics ........................................................................................................... 41  
8.5 Genetics ...................................................................................................................... ... 41  
8.6 Biomarkers .................................................................................................................... . 41 
8.7 Immunogenicity Assessments ........................................................................................ 42  
8.8 Health Economics .......................................................................................................... 42  
9. Statistical Considerations ............................................................................................... 42  
9.1 Statistical Hypotheses .................................................................................................... 42  
9.2 Analysis Sets ................................................................................................................. . 42 
9.3 Statistical Analyses ........................................................................................................ 4 3 
9.3.1  General Considerations............................................................................................... 43  
9.3.2  Primary Endpoint(s)/Estimand(s) Analysis ................................................................ 43  
9.3.3  Secondary Endpoint(s)/Estimand(s) Analysis ............................................................ 43  
[IP_ADDRESS]  Analysis of Secondary Endpoints for the Primary Objective ................................. 43  
[IP_ADDRESS]  Analysis of Secondary Endpoints for the Secondary Objective ............................. 44  
9.4 Interim Analysis ............................................................................................................. 45 
9.5 Sample Size Determination ........................................................................................... 45  
10. Supporting Documentation and Operational Considerations .................................... 47  
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........................ 47  
10.1.1  Regulatory and Ethical Considerations ...................................................................... 47  
10.1.2  Financial Disclosure ................................................................................................... 47  
10.1.3  Informed Consent and Assent Process ....................................................................... 48  
10.1.4  Data Protection ........................................................................................................... 49  
10.1.5  Dissemination of Clinical Study Data ........................................................................ 49  
10.1.6  Data Quality Assurance .............................................................................................. 49  
10.1.7  Source Documents ...................................................................................................... 50  
10.1.8  Study and Site Start and Closure ................................................................................ 50  
10.1.9  Publication Policy ....................................................................................................... 51  
10.2  Appendix 2: Clinical Laboratory Tests .......................................................................... 51  
10.3  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow up, and Reporting .............................................................................................. 52  
10.3.1  Definition of AE ......................................................................................................... 52  
10.3.2  Definition of SAE ....................................................................................................... 54  
10.3.3  Recording and Follow Up of AE and/or SAE ............................................................ 55  
10.3.4  Reporting of SAEs ...................................................................................................... 56  
10.4  Appendix 4: AEs, SAEs, and Device Deficiencies: Definitions and Procedures for 
Recording, Evaluating, Follow up, and Reporting ........................................................ 57  
10.4.1  Definition of Medical Device AE ............................................................................... 57  
10.4.2  Definition of Medical Device SAE ............................................................................ 58  
10.4.3  Definition of Device Deficiency................................................................................. 59  
10.4.4  Recording and Follow Up of AE/SAE/Device Deficiencies ...................................... 59  
10.4.5  Reporting of AEs/SAEs Related to the Medical Devices........................................... 60  
10.5  Appendix 5: Abbreviations and Definitions .................................................................. 61  
10.5.1  Abbreviations ............................................................................................................. 61  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  7 of 69 
 
10.5.2  Definitions .................................................................................................................. 63 
10.6  Appendix 6: Protocol Amendment History ................................................................... 63  
11. References .................................................................................................................... .... 69  
 
Table of Tables 
Table 1 –1: Schedule of Activities - main study (Part A) ......................................................... 10  
Table 1 –2: Schedule of Activities – extension study (Part B) ................................................. 12  
Table 2 –1: Summary of Risk Assessment................................................................................ 16  
Table 6 –1: Study Intervention(s) Administered ....................................................................... 24  
Table 10 –1: Protocol-required Safety Laboratory Tests .......................................................... 52  
 
 
  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  8 of 69 
 
1. Protocol Summary  
1.1 Synopsis 
Protocol Title:  
A Phase 3, single-group treatment, open-label, study to evaluate the safety of BAY 94-9027 
infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A. 
Short Title:  A Phase 3 safety study of BAY 94-9027 in childre n 7 to <12 years of age with severe hemophilia 
A  
Rationale:   
At the time of the initial biologic license appl ication /marketing authorization application 
(BLA/MAA), the indication for BAY 94-9027 was restricted to previously treated hemophilia A 
patients 12 years and older, partly, because of the observation of an immune response to 
polyethylene glycol (PEG) in some children < 6 years, manifested as hypersensitivity and/or loss 
of efficacy (LoE). A significant decrease in the risk of an immune response to PEG was observed with an increase in age. Among the 25 previously treated patients, aged 7 to <12 years, in the pi[INVESTIGATOR_266895] <12 years of ag e with severe hemophilia A, no such cases were 
observed. However, due to the small sample size, as a safety margin, this age group (7 to <12 years) was excluded in the initial MAA. This study will address the potential risk of hypersensitivity and lack of drug effect associated with anti-PEG antibodies during the first 4 exposures to BAY 94-9027 in previously treated children 7 to <12 years of age with severe hemophilia A, and will provide supportive data fo r efficacy of prophylaxis treatment including 
long-term safety data.  
Objectives, Endpoints, and/or Estimands: Primary and secondary objectives and end points are described below. See Section [ADDRESS_324808] of objectives and endpoints. 
Objectives Endpoints 
Primary objective (main study)  
Safety  
To assess safety and tolerability of  
BAY 94-9027 replacement therapy in previously 
treated patients 7 - <12 years of age with severe 
hemophilia A  
 Primary endpoint  
x AESI (hypersensitivity and LoE*) associated with the 
first 4 EDs leading to discontinuation 
Secondary endpoints  
x Adverse drug reactions (ADRs) 
x Anti-drug antibody (ADA) development 
x Inhibitor development 
Secondary objective (main study and 
extension study)  
To describe clinical efficacy of BAY 94-9027 Secondary endpoints 
x Annualized bleeding rate (ABR)  
x BAY 94-9027 consumption  
x Number of infusions/month and year (Annualized 
Infusion Rate) 
AESI = adverse events of special interest, ED = exposure day 
*  As defined in Section 8.3.8 . 
Overall Design 
Short Summary: The purpose of this open-label, single-group, uncont rolled, prospective, multicenter study is to 
assess the safety of BAY 94-9027 in children ag ed 7 to <12 years with severe hemophilia A. 
Study details: 
x The treatment duration will be: 
o Main study (Part A) : 6 months and  ≥ 50 exposure days (ED s) 
o Extension study (Part B) : 18 months  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324809] 4 EDs with study intervention, 
with visit frequency decreasing afterwards (see Section 1.3 SoA for details) 
Number of Participants: 
x At least [ADDRESS_324810] (AESI). 
Intervention Groups and Duration: 
x Part A : Each participant will receive BAY 94-9027 intravenously (IV) as prophylactic 
treatment 2x/week, with a dose of 40 IU/kg (up to 60 IU/kg – at the investigator’s 
discretion)  
x Part B : Each participant may continue on prophylaxis dose regimen as prescribed in part 
A (40 – 60 IU/kg, 2x per week) or the prophylaxis regimen may be adjusted to 60 IU/kg 
IV every 5 days at the investigator’s discretion  
Data Monitoring/Other Committee: No 
1.2 Schema 
 
EDs = exposure days 
 

CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  10 of 69 
 
1.3 Schedule of Activities (SoA) 
Table 1 –1: Schedule of Activities  - main study (Part A) 
Period SCR Treatment 
Visit number 
Exposure day (ED) V1 V2 
ED1 V3 
ED2 V4 
ED3 V5 
ED4 V6 V7 V8 V9 V10 V11 
ED 50 /E.Disc. 
In person (IP) or phone call IP IP IP IP IP IP or  a IP IP  IP IP 
Relative time 
W = week, D=day Up to - 30 
Days D1 
(BSL) W1 W2 W2 W4 W8 W12  W16 W20 W26 
(Month 6) 
Allowed window  ±1 days for all visits from V2 to V5, inclusive  ±3 days for all visits from V6 to V11, inclusive 
Informed consent/assent X           
Check inclusion/exclusion criteria X X          
Demography X           
Physical examination (height and weight) X       X   X 
Neurological assessment   X b         X 
Medical and surgical history X           
Previous and concomitant medication  X X X X X X X X X X X 
Vital signs   X c X c X c X c      X 
Haemo-QoL questionnaire d  X         X 
Patient/Caregiver Global Impression of Severity  X         X 
Patient/Caregiver Global Impression of Change           X 
Laboratory assessments (chemistry and hematology) e X X f         X 
PEG quantification  X b         X 
Urine / serum biomarkers for renal function   X b         X 
Immunogenicity (FVIII inhibitor, ADA) – pre-infusion g,h X X X X X  X    X 
FVIII levels g if no prior result available (Section 5.1) X           
Recovery (pre and 15-[ADDRESS_324811]-infusion FVIII 
levels) g,h,i  X X X X      X 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  11 of 69 
 
Table 1 –1: Schedule of Activities  - main study (Part A) 
Period SCR Treatment 
Visit number 
Exposure day (ED) V1 V2 
ED1 V3 
ED2 V4 
ED3 V5 
ED4 V6 V7 V8 V9 V10 V11 
ED 50 /E.Disc. 
In person (IP) or phone call IP IP IP IP IP IP or  a IP IP  IP IP 
Relative time 
W = week, D=day Up to - 30 
Days D1 
(BSL) W1 W2 W2 W4 W8 W12  W16 W20 W26 
(Month 6) 
Allowed window  ±1 days for all visits from V2 to V5, inclusive  ±3 days for all visits from V6 to V11, inclusive 
In-hospi[INVESTIGATOR_266896] 94-9027  X X X X      X j 
AE review X k X X X X X X X X X X 
Dispense study intervention l     X  X X X X (X) m 
Return used /unused study intervention       X X  X X 
Diary review n   X X X X X X X X X 
ADA = anti-drug antibodies (anti-PEG, anti-PEG IgM in all treated study participants; IgE only in study participants who experi ence a hypersensitivity reaction) ED = exposure 
days, BSL = baseline, E.Disc. = early discontinuation, FVIII = fa ctor VIII, IP = in-person visit, QoL = Quality of Life, SCR = screening, V = visit,  
a: At the investigator’s discretion based on participant’s condition . 
b: May be performed at a visit other than baseline if the participant  is already enrolled at the time Amendment 1 is implemented, PEG quantification and urine/serum 
biomarkers must be performed before infusion at the scheduled visit. 
c: Vital signs to be taken before and after infusion. 
d:  QoL questionnaire: Haemo-QoL Kids Short Form (8-16 years old version).  
e:  See Section 10.2 for details on laboratory parameters. 
f:  Only chemistry collected at Visit 2 
g: FVIII level and FVIII inhibitor tests must be done after a sufficient wash-out period depending on the participant’s previous FVIII product –  at least [ADDRESS_324812] half-life (SHL) and extended ha lf-life (EHL) FVIII products respectively (screening and baseline visits). 
h:  FVIII inhibitor tests and pre-infusion FVIII levels for recovery must be done after a wash- out period of at least 72 hours after previo us dose of study intervention (V3, V4, 
V5, V7, and V11/E.Disc.). If a 72-hour wash-out period is not po ssible (e.g. participant received previous infusion within 48 h ours), no restriction is needed during the first 4 
EDs or at any visits for monitoring of ADA.  In this sc enario, recovery should also be measured without wash-out.  
In case of early discontinuation, recovery is not required.  
i:  Local FVIII levels should be obtained to guide treatment for the next dose during the first 4 EDs.   
j: In-hospi[INVESTIGATOR_266897] (hypersensiti vity or loss of efficacy) or other reasons. 
k:  Only study procedure related AEs. 
l:  Unscheduled visits are permitted at any time at the discretion of  the investigator. In addition, participants may visit the stu dy center for study intervention and supplies. 
m:  Drug dispensing for extension study (Part B). 
n:  Dispense diary at V2.  
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  12 of 69 
 
Table 1 –2: Schedule of Activities – extension study (Part B) 
Extension visit number EV1–EV2 EV3 EV4–EV5 EV6  EV 7 –EV 11 EV 12 EV 13 –EV 17 EV 18 / E. 
Disc. Follow-upa 
In person (IP) or phone call   IP  IP  IP  IP  
Month  
and allowed window Months 7-8b 
± 1week Month 9 
± 1week Months 10-11b 
± 1week Month 12 
± 1week   Months 13-17b 
± 1week  Month 18 
± 1week   Months 19-23b 
± 1week  Month 24 
± 1week   7 to 14 days after 
EV18 /  E. Disc. 
Physical examination (height and 
weight)  X  X  X  X  
Neurological assessment        X  
Concomitant medication  X X X X X X X X X 
Vital signs    X  X  X  
Immunogenicity (FVIII inhibitor, ADA) c    X  X  X  
Recovery (pre and 15-[ADDRESS_324813]-
infusion FVIII levels) c  
  X  X  X  
In-hospi[INVESTIGATOR_266896] 94-9027    X  X  X d  
AE review X X X X X X X X X 
Return used/ unused study intervention  X   X  X  X  
Dispense study intervention e Intervention dispensed according to IxRS specification   
Diary review  X X X X X X X X  
Haemo-QoL questionnaire f    X  X  X  
Patient/Caregiver questionnaires g    X  X  X  
Laboratory assessments (chemistry 
and hematology) h        X  
PEG quantification        X  
Urine/serum biomarkers for renal 
function         X  
ADA = anti-drug antibodies (anti-PEG, anti-PEG IgM in all treated study participants; IgE only in study participants who experi ence a hypersensitivity reaction), ED = exposure 
days, E.Disc. = early discontinuation, EV = extension visit, FVIII = factor VIII, IP = in-person visit   
a: Follow -up call for early discontinuation in Part A and Part B. 
b: One phone call per month for all months included in this window of time.  
c: FVIII inhibitor tests and pre-infusion FVIII levels for recovery must be done after a wash-out period of at least 72 hours afte r previous dose of study intervention 
(EV6/E.Disc.). 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  13 of 69 
 
Table 1 –2: Schedule of Activities – extension study (Part B) 
Extension visit number EV1–EV2 EV3 EV4–EV5 EV6  EV 7 –EV 11 EV 12 EV 13 –EV 17 EV 18 / E. 
Disc. Follow-upa 
In person (IP) or phone call   IP  IP  IP  IP  
Month  
and allowed window Months 7-8b 
± 1week Month 9 
± 1week Months 10-11b 
± 1week Month 12 
± 1week   Months 13-17b 
± 1week  Month 18 
± 1week   Months 19-23b 
± 1week  Month 24 
± 1week   7 to 14 days after 
EV18 /  E. Disc. 
d: In-hospi[INVESTIGATOR_266898] (hypersensitivity or loss of efficacy) or other reasons. 
e: Unscheduled visits are permitted at any time at the discret ion of the investigator. In addition, participants may visit the  study center for study intervention and supplies. 
f: QoL questionnaire -: Haemo-QoL Kids Short Form (8-16 years old version). 
g: Patient/Caregiver Global Impression of Severity and Patient/Caregiver Global Impression of Change.  
h: See Section 10.2 for details on laboratory parameters. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324814] ication /marketing authorization application 
(BLA/MAA), BAY 94-9027 has received marketing authorization for treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 12 years of age with 
hemophilia A.  
The indication for BAY 94-9027 (Jivi) was re stricted to previously treated hemophilia A 
patients 12 years and older, partly because of  the observation of an immune response to PEG 
in some children < 6 years, manifested as hype rsensitivity and/or loss of efficacy (LoE) ( JIVI 
SmPC 2018 , JIVI® Prescribing information 2018 ). The immune response associated with 
anti-PEG IgM antibodies was observed within th e first 4 EDs in some children 2-5 years of 
age leading to study discontinuation in all cases. Clinical symptoms were mild to moderate acute hypersensitivity and/or LoE. All patients co uld revert back to their previous factor VIII 
treatment. 
A significant decrease in the risk of an immune response to PEG was observed with an 
increase in age. Among the 25 PTPs, aged 7 to <12 years, in the pi[INVESTIGATOR_266895] < 12 years of age with severe hemophi lia A, no such cases were observed. However, 
due to the small sample size, as a safety margin, this age group (7 to <12 years) was excluded in the initial BLA/MAA.  
This study addresses the uncertainty of the risk of potential hypersensitivity and lack of drug 
effects associated with anti-PEG antibodies during the first 4 exposures to BAY 94-9027 in 
previously treated children with severe hemophilia A, 7 to <12 years of age. In addition, will 
provide supportive data for efficacy of prophylaxis treatment and long-term safety data.  
2.2 Background 
BAY 94-9027 is a recombinant FVIII (rFVIII) with extended half-life through reduced 
clearance from plasma by [CONTACT_266921]. It has received marketing authorizati on for treatment and prophylaxis of bleeding 
(including perioperative  management) in PTPs ≥ 12 years of age with hemophilia A 
(congenital FVIII deficiency) ( JIVI SmPC 2018 , JIVI® Prescribing information 2018 ). 
Pharmacokinetics, clinical efficacy and safety  of BAY 94-[ADDRESS_324815] been assessed in one Phase 1 study and two Phase 3 studies including previously treated severe hemophilia A patients 2 to 65 years of age ( Coyle et al. 
2014 , Reding et al. 2017 , Santagostino et al. 2020 ).  
Pharmacokinetics, safety, and efficacy of BAY 94 -9027 in pediatric patients <[ADDRESS_324816] Kids study (study [ZIP_CODE]; [STUDY_ID_REMOVED]), a Phase 3 multicenter, open-label, noncontrolled study to assess BAY  94-9027 treatment for prophylaxis 
and treatment of bleeds in previously treated children (>50 ED) with severe hemophilia A. 
The study comprised a main study (in PTPs <12 years of age), Part 2 (in PTPs 2-5 years of 
age) and the extension study, and included a total of 73 patients, 44 in the age group < 6 years and 29 in the age group 6 to <12 years. The med ian total study duration was 5.4 years (N=73). 
Efficacy of prophylaxis treatment and treatment of bleeds was demonstrated for both age 
groups ( Santagostino et al. 2020 ). The geometric mean terminal half-life (t
½) for 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  15 of 69 
 
BAY 94-9027 was 14.5 hours and 15.6 hours in patients aged <6 years ( n = 14 ) and 6 to <12 years (n = 13), respectively ( Shah et al. 2018 ).  
No subjects developed inhibitory antibodies to FVIII ( ≥0.6 BU/mL) during the study . A 
clinical immune response associated with anti-PEG IgM antibodies, manifested as symptoms of acute hypersensitivity and/or LoE (AESI) was observed within the first 4 EDs in young children 2-5 years of age leading to study discontinuation in all cases ( Santagostino et al. 
2020 ). In cases of clinical immune response associated with anti-PEG IgM antibodies 
presenting with hypersensitivity reactions, these reactions were observed within [ADDRESS_324817] was not impaired in the subjects aff ected. There was no immunoglobulin class switch 
to IgG, and the IgM titers disappeared over time suggesting no long-term memory response 
(Santagostino et al. 2020 ). No participant aged 7 to <12 years old (n = 25) experienced an 
AESI (hypersensitivity and/or LoE). A significant decrease in the risk of an immune response to PEG was observed with an increase in age.  Thus, the clinical immune response associated 
with anti-PEG IgM antibodies, may be related to a developmental change in immunity, and although it is difficult to define a clear cut-off age for the change in risk, this phenomenon predominantly occurred in young children (2 -5 years of age) with hemophilia A.  
Immunogenicity to the PEG moiety in Jivi appears to be age related, as it is suggested by 
[CONTACT_266922]. More specifically, this early data 
suggests  that when an immune response occurs, it is less severe in this age group than that 
typi[INVESTIGATOR_266893] 2-5 years of age. This reduced immune response has been characterized by [CONTACT_266923]-PEG antibodies (1:1 to 1:4) with mild to moderate reductions in FVIII recovery during EDs 2-4. Continued dosing with Jivi has demonstrated 
decreased levels of anti-PEG antibodies and improve d FVIII recovery. To better protect study 
participants against the potential for a bleed related to lower-than-expected FVIII levels, routine local FVIII recovery measurements should be performed at the clinical site for the first [ADDRESS_324818] the dose 
and dosing interval for the subsequent EDs.  
2.3 Benefit/Risk Assessment 
Relevant emerging safety data, e.g., serious adverse events (SAEs), suspected unexpected 
serious adverse reactions (S[LOCATION_003]Rs), and serious  safety-related protocol deviations, will be 
communicated as soon as possible between the sponsor, all study sites and investigators and trial participants/parents/caregivers.  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of BAY 94-9027  may be found in the Investigator’s Brochure  (IB). 
2.3.[ADDRESS_324819] relevant treatmen t related complication for class of FVIII 
replacement products, is the development of FVIII inhibitors. For previously untreated patients (PUPs), the risk to develop inhibit ors is considered very common (approximately 
30% to 50%) ( Franchini et al. 2013 , Peyvandi et al. 2016 , Srivastava et al. 2020 ), whereas the 
risk for PTPs is considered uncommon (<1%). No confirmed case of inhibitor development 
was reported during the development program with BAY 94-9027 in PTPs.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  16 of 69 
 
Other known risks for class of FVIII re placement products are allergic type of 
hypersensitivity reactions which may progress to anaphylaxis including shock, cardiovascular events, and the possibility of catheter related co mplications. Data of more than 200 patients in 
the age range of 2 to 62 years demonstrated that these risks are not different for BAY 94-9027 administered to PTPs. No case of anaphylax is was reported, and no serious cardiovascular 
event was observed. 
A new risk identified during the developm ent program for BAY 94-9027 is an immune 
response to PEG which resulted in LoE, observed as bruising or bleeding not responsive to treatment with BAY 94-9027 and very low r ecovery (sometimes undetectable) following 
infusion of BAY 94-[ADDRESS_324820] frequent in the age group less 
than 6 years and resulted in a premature termi nation of study treatment in approximately 23% 
(10/44) of cases in this age group. There were no cases of PEG immune response among the 25 patients, aged 7 to <12 years, and only 1/134 patients ≥[ADDRESS_324821]-marketing surveillance 
(PMS) with >1,000 new patients starts, the incidence of clinical events likely associated with antibodies to the PEG moiety has been consistent with that observed in the clinical trials for patients ≥[ADDRESS_324822] occurred on  EDs 2-4.  
A potential class risk for pegylated FVIII replacement products is associated with PEG 
accumulation following long-term treatment. The dose of PEG contained with BAY 94-9027 is low relative to other pegylated products (e.g., certolizumab pegol) resulting in a low total weekly and monthly PEG exposure below the le vel of concern in the pediatric population of 
0.4μmol-kg-month of PEG ( EMA 2012 ). In distribution and excretion studies in rats, the 60 
kDa PEG moiety of Jivi® was shown to be elim inated from organs and tissues, and excreted 
in urine and feces ( Baumann et al. 2019 ). 
In a long-term, 6-months chronic toxicity study in immunodeficient rats no indication of PEG 
accumulation or other effects related to administration of Jivi® were seen. (( JIVI SmPC 
2018 ), Section 5.3 ).  
In addition, no evidence for accumulation of PEG in plasma (median levels < 0.1 mg/L) nor 
in other organs such as kidneys, liver, and ce ntral nervous system was demonstrated for up to 
7 years of continuous treatment in the clinical extension studies of Jivi® in children and adults (PTPs 2 - 62 years of age) ( Mancuso et al. , Reding et al. 2021 ).   
Blood samples will be collected at screening to confirm study eligibility, and during 
scheduled study visits as part of safety assessment for the study. The frequency of these assessments is likely more than is typi[INVESTIGATOR_266899]. The study has kept the frequency of these assessments to the minimum re quired to reliably assess the safety of BAY 
94-9027 in study participants. For the majority of participants in the study, the volumes drawn 
at any one visit are not expected to exceed more than 1% of total blood volume or 3% in any 1-month interval. Therefore, it is expected th at the risk associated with blood draws is not 
more than would be expected with standard of care. 
Table 2 –1: Summary of Risk Assessment  
Potential Risk of 
Clinical Significance Summary of Data/Rationale for 
Risk Mitigation Strategy 
 
Study Intervention  
Development of FVIII 
inhibitor s  
 The formation of neutralizing 
antibodies  (inhibitors) to FVIII is a 
known and listed AE for FVIII Participants will be tested for  FVIII 
inhibit ors.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  17 of 69 
 
Table 2 –1: Summary of Risk Assessment  
Potential Risk of 
Clinical Significance Summary of Data/Rationale for 
Risk Mitigation Strategy 
 
  products. No confirmed case of 
FVIII inhibitor development was 
reported during the development 
program  with BAY 94-9027 x Inhibitor titer is assessed at 
scheduled study visits. 
x Planned time points for all safety 
assessments are provided in the 
SoA (Section 1.3). 
 
The informed consent will  outline the 
important identified and potential risks.  
Anti-drug antibodies to PEG leading to h
ypersensitivity reaction 
and LoE  Hypersensitivity and LoE have been reported in previous clinical studies with BAY 94
-9027, mainly in 
children <[ADDRESS_324823] 4 ED
s. This was not observed in 
children in the age group 7-<[ADDRESS_324824]- infusion FVIII levels will be 
measured intermittently as per SoA during 
the main study.  
 Reporting 
these AEs as AESIs (Section 
[IP_ADDRESS]  and Section 8.3.8 ) 
 
Inclusion of stoppi[INVESTIGATOR_266900] 
(Section 10.1.8 ) 
 
The informed consent will  outline the 
important identified and potential risks. 
Hypersensitivity reaction 
in the absence of 
development of anti -PEG 
antibodies  Hypersensitivity reaction to 
exogenously administered FVIII is a 
known and listed AE for FVIII 
products and have occurred with 
BAY [ADDRESS_324825] 
procedures for assessment of safety  Study procedures will be conducted at 
specialized hemophilia treatment centers by [CONTACT_21724]. 
2.3.2 Benefit Assessment 
Hemophilia A is an X-linked, congenital, potenti ally life-threatening disease that is caused by 
a deficiency of FVIII and results in impaired  blood clotting. Patients with hemophilia A 
require infusions of replacement FVIII to prev ent and treat spontaneous and trauma-related 
bleeding epi[INVESTIGATOR_1841].  
BAY 94-9027 is an extended half-life, recombinant FVIII (rFVIII) product approved for the 
prevention and treatment of bleeding epi[INVESTIGATOR_1841] (i ncluding perioperative management) in PTPs 
≥12 years of age with hemophilia A.  Efficacy of BAY 94-9027 for treatment of bleeds and 
prophylaxis in hemophilia A was demonstrated in two Phase 3 studies including previously treated severe hemophilia A patients 2 to 65 years of age ( Reding et al. 2017 , Santagostino et 
al. 2020 ). The potential benefits of the study intervention to participants are less frequent 
dosing and less reliance on central venous catheters, which may reduce physical and 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  18 of 69 
 
emotional burden for the child and his family, le ading to better adherence. This, in turn, may 
translate into improved FVIII activity coverage and good prophylactic protection from bleeds.  
2.3.3 Overall Benefit: Risk Conclusion 
Taking into account the measures taken to minimize risk to participants in this study, the 
potential risks identified in association with BAY 94-9027 are justified by [CONTACT_266924] 94-9027 that may be afforded to study participants. 
3. Objectives, Endpoints, and Estimands  
Objectives Endpoints 
Primary objective (main study)  
Safety  
To assess safety and tolerability of  
BAY 94-9027 replacement therapy in 
previously treated patients 7 - <12 years of 
age with severe hemophilia A 
 Primary endpoint  
x AESI (hypersensitivity and LoE*) associated with the first 
4 EDs leading to discontinuation 
 
Secondary endpoints  
x Adverse drug reactions (ADRs) 
x Anti-drug antibody (ADA) development 
x Inhibitor development 
Secondary objective (main study and 
extension study)  
To describe clinical efficacy of BAY 94-9027 Secondary endpoints 
x Annualized bleeding rate (ABR)  
x BAY 94-9027 consumption  
x Number of infusions/month and year (Annualized Infusion 
Rate) 
Other   
To further investigate long-term safety x Quantitative PEG measurement  
x Renal safety-related urine and serum biomarkers 
x Liver enzymes  
x Neurological assessment  
To assess the impact of BAY  94-9027 in 
Health -related QoL   Patient -reported outcomes (PROs) questionnaires 
To further investigate the study intervention 
and similar drugs ( e.g., mode-of-action-
related effects, safety) and to further 
investigate pathomechanisms deemed 
relevant to  hemophilia and associated 
health problems  Various biomarkers (e.g., diagnostic, safety, 
pharmacodynamic, monitoring, or potentially predictive 
biomarkers)  
AESI = adverse events of special interest, ED = exposure day 
*  As defined in Section 8.3.[ADDRESS_324826] for the primary objective is: What is the proportion of individuals with AESIs (hypersensitivity and LoE) associated with 
the first 4 EDs of BAY 94-9027 treatment and leading to discontinuation of BAY 94-9027 
treatment in previously treated males, 7 to <12 years of age with severe hemophilia A, and 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  19 of 69 
 
without inhibitors to FVIII, who do not disc ontinue study for other reason than an AESI 
before the fourth ED with or without emergency use of other FVIII medication? 
The estimand is described by [CONTACT_6570]: 
Population  Previously treated (≥50 EDs) male individuals, 7 to <12 yea rs of age, with 
severe hemophilia A (FVIII:C <1%) without inhibitors to FVIII (<0.6 BU/mL).  
Endpoint  AESI (i.e., hypersensitivity or LoE, as defined in Section 8.3.8 ) associated with 
the first 4 EDs of BAY 94 -9027 treatment leading to discontinuation. 
Treatment 
condition  2x/week BAY 94 -9027 prophylactic treatment at a dosage of 40 IU/kg, up to 60 
IU/kg , with or without emergency use of other FVIII products (treatment policy 
strategy *). 
Intercurrent 
events and 
strategies how 
to address them
 x Individuals with the intercurrent event ’treatment discontinuation for any 
reason other than AESI before the fourth ED’ will not be included in the 
assessment of the primary endpoint  (principal stratum strategy*).  
x The intercurrent event ‘emergency use of  other FVIII products’ is addressed 
by [CONTACT_266925] * .  
Other relevant intercurrent events are not anticipated at this point in time.  
Population 
level summary Proportion of individuals who experience a primary endpoint AESI . 
*: Treatment policy strategy , and principal stratum strategy refer to the strategies for addressing intercurrent 
events as described in the ICH E9 (R1) guideline  
Rationale for estimand:  
In the pi[INVESTIGATOR_9205] [ADDRESS_324827] Kids, an immune response 
associated with anti-PEG IgM antibodies was observed primarily in children 2-5 years of age. The immune response manifested as symptoms of hypersensitivity and/or LoE. All events occurred during the first 4 EDs of BAY 94-9027 and all led to study discontinuation. The primary estimand has been chosen to estimate the unknown risk of such events in previously treated children, 7 to <[ADDRESS_324828] for the secondary objective is: What is the ABR of previously treated males 7 to <[ADDRESS_324829] 50 EDs are 
reached (approximately 6 months) and for further 6 months by [CONTACT_266926]?  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  20 of 69 
 
The estimand is described by [CONTACT_6570]: 
Population Previously treated ( ≥50 EDs) male individuals , 7 to <12 years of age, with 
severe hemophilia A (FVIII:C <1%) without inhibitors to FVIII (<0.6 BU /mL). 
Endpoint Number of bleeds per individual observation period of continuous prophylactic 
treatment (overall and per treatment regime n) of at least [ADDRESS_324830] 50 EDs are reached (approximately 6 months) and for further 18 
months of BAY 94 -9027 treatment. [In this study, the 6- and 2- year periods are 
reflecte d by [CONTACT_9524] A and Part B of the study.] 
Treatment 
condition  2x/week prophylactic treatment with BAY 94-9027 at a dosage of 40 IU/kg, up to 
60 IU/kg , with option to change to every 5 days prophylactic treatment with BAY 
94-9027 at a dosage of 60 IU/kg IV, after at least 50 EDs (with start of Part B) 
with or without emergency use of other FVIII medication (treatment policy 
strategy *). 
Intercurrent 
events and 
strategies how 
to address them
 x The intercurrent events ‘treatment discontinuation for any reason bef ore 
Month 3’ and ‘development of an inhibitory antibody to FVIII or ADA that 
neutralizes activity sufficiently to interfere with effective treatment’ will be 
addressed by [CONTACT_266927]*.  
x The intercurrent events ‘treatment discontinuation for any reason after 
Month 3’ and ‘emergency use of other FVIII medication’ will be addressed 
by [CONTACT_17983]*. 
x The intercurrent event ‘emergency major surgery’ is addressed by [CONTACT_266928]*. The time of the 
surgery will not be considered for the observation period and bleeds during 
the time of the surgery (i.e., bleeds related to the surgery procedure) will not 
be counted. An individual with th is intercurrent event will be analyzed as if 
the surgery had not happened. 
Other relevant intercurrent events are not anticipated at this point in time.  
Population 
level summary Mean and 95% confidence interval for ABR estimated by a Negative B inomial 
regression. 
*: Treatment policy strategy, principal stratum strategy, a nd hypothetical strategy refer to the strategies for 
addressing intercurrent events as described in the ICH E9 (R1) guideline  
Rationale for estimand:  
Efficacy is assessed by [CONTACT_266929]. The ABR during continuous 
prophylaxis treatment with BAY 94-[ADDRESS_324831] in an emergency 
case will be counted for the ABR as they occurred during prophylaxis treatment with BAY 94-9027. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  21 of 69 
 
4. Study Design  
4.1 Overall Design 
This is an open-label, single-group, uncont rolled, prospective, multicenter study.  
It comprises of the main study (Part A) and the extension study (Part B).  Part A will last for [ADDRESS_324832] 50 EDs. Extension study (Part B) will last 18 
months. 
For detailed visit schedule, refer to Section 1.3. Treatment administration is described in 
Section 6. 
4.2 Scientific Rationale for Study Design 
The study design is similar to that of the previous study with the study intervention in 
pediatric patients (PROTECT Kids study) in order to allow for pooling of data. Although, the safety events under evaluation had only been observed in the young age group < [ADDRESS_324833] 4 ED by [CONTACT_266930] 7 to <12 years. The additional 30 participants will provide  a pooled sample size of 55 participants in 
the proposed age group. 
4.3 Justification for Dose 
40 IU/kg IV was the mean prophylaxis dose and 60 IU/kg IV was the upper dose range during 
the PROTECT Kids study. During the extension study, participants may also be treated with 
60 IU/kg IV every [ADDRESS_324834] participant completes Month 6 visit (or 
discontinues early). 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  22 of 69 
 
5. Study Population  
Prospective approval of protocol deviations to re cruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted. 
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
1. Participant must be 7 to <12 years of age at the time of parent / legal guardian signing 
the informed consent  
Type of participant and disease characteristics 
2. Participants with known medical histor y of severe hemophilia A (participant ’s own 
FVIII activity [FVIII:C] <1%. FVIII:C) based on reliable prior documentation in clinical records of the participants. If no reliable documentation is available, FVIII activity must be measured at the time of sc reening after a 48-72 hours wash-out period 
(depending on his previous product). 
Sex 
3. Male 
Treatment 
4. Participants must be previously treated with FVIII concentrate(s) (plasma derived or 
recombinant) for a minimum of 50 EDs at the time of signing the informed consent.  
Informed consent and Assent 
5. Participant has understood the study and if  appropriate for his age, has signed an 
informed assent. The parent(s) or guardian(s ) is capable of giving signed informed 
consent as described in Section 10.1.3  which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 
6. Willingness and ability of participants and/ or parents /caregivers to complete training 
in the use of the electronic patient diary (EPD) and to document infusions during the study.   
5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply: 
Medical conditions 
1. History of FVIII inhibitors. Inhibitor to FVIII is defined as a titer >0.6 BU/mL 
(Nijmegen-modified Bethesda assay) or clinical history suggestive of inhibitor 
requiring modification of treatment. Partic ipants with a maximum historical titer of 
<1.0 BU/mL on no more than [ADDRESS_324835] 
3 subsequent negative results [<0.6 BU/mL] are eligible.  
2. Current evidence of inhibitor to FVIII measured using the Nijmegen-modified 
Bethesda assay (>0.6 BU/mL) at the time of screening (central laboratory).  
Participants should not receive FVIII within at least 48 hours prior to the collection of 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  23 of 69 
 
screening samples (See Section 1.3) and should have FVIII administered within the 
prior 2-3 weeks 
3. Any other inherited or acquired bleeding disorder in addition to hemophilia A 
(e.g., von Willebrand disease, hemophilia B)  
4. Platelet count <100,000 cells/ μL 
5. Serum creatinine > 2x upper limit of normal 
6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5x upper limit 
of normal  
7. Known hypersensitivity or allergic reaction to drug substance, excipi[INVESTIGATOR_266901] 
8. Any other significant medical condition that the investigator feels would be a risk to 
the participant or would impede the study 
Prior/concomitant therapy 
9. Requires any pre-medication to tolerate FVIII treatment (e.g., antihistamines) 
10. Planned major surgery during the study  
11. Any individual who is currently receiving or received chemotherapy, immune 
modulatory drugs,  or has /had chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months, other than anti-viral therapy 
12. Any individual who received commercially available subcutaneous factor substitution 
therapy (emicizumab) within the last 6 months  
Prior/concurrent clinical study experience 
13. The participant is currently participating in another investigational drug study or has 
participated in a clinical study involving an investigational drug within 30 days of study entry or previous participation in a clinical study with BAY 94-9027. 
Other exclusions 
14. Close affiliation with the investigational site; e.g., a close relative of the investigator, 
dependent person  
15. Otherwise vulnerable participants other than being a child 
16. The participant is identified by [CONTACT_266931] 
5.3 Lifestyle Considerations 
Not applicable. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global)
No. BAY 94-9027 / [ZIP_CODE]
06 APR 2023 Page: 24 of 69
5.4 Screen Failures
A screen failure occurs when a participant or his legal guardian consents to participate in the 
clinical study but are not subsequently entered in the treatment phase of the study. A minimal 
set of screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the Consolidated Standa rds of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, and eligibility criteria.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once. Rescreened participants should be assigned a new participant number.
5.[ADDRESS_324836] resolved and the pa rticipant is otherwise eligible:
xCurrent febrile illness (temperature 38.0
oC [100.4oF]) or other acute illness within 
[ADDRESS_324837] ical reasons (eg, study intervention not 
available at site). In this instance, the screening period may be prolonged by
[CONTACT_168984] 4 weeks without a need to repeat the screening assessment.  This is only allowed once.
6. Study Intervention(s) and Concomitant Therapy
Study intervention is defined as any invest igational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol.
6.1 Study Intervention(s) Administered
Table 6 –1: Study Intervention(s) Administered
Intervention Name [CONTACT_266956] (For
Prophylaxis)Main study (Part A) : 40 IU/kg (up to 60 IU/kg at the investigator’s discretion) , 2 times 
per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, 
participants will continue their treatment as home treatment.
Dose may be increased up to 60 IU/kg (rounded up to full vials) if needed at any time 
during the study at the investigat or’s discretion. Potential reason sfor a higher dose 
are e.g., presence of target joints, known sh ort half-life of previous FVIII, high physical 
activity level, individual need for high trough FVIII levels. 
Post-infusion FVIII levels may be lower than expected after the first exposures (e.g., 
recovery of <1.2 kg/dL) and ma y be related to low titer anti -PEG antibodies.  CCI
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  25 of 69 
 
Table 6 –1: Study Intervention(s) Administered  
Extension study (Part B) :  Each participant may continue on prophylaxis dose 
regimen as prescribed in part A (40 – 60 IU/kg, 2x per week) or adjustments to 
prophylaxis dose / dose frequency can be made at the investigator’s discretion  (based 
on the bleeding events  and individual needs): 
- Dose may be increased to 60 IU/kg (rounded to full vials) 
- Dose frequency may be decreased to every 5 days (prophylaxis dose: 60 IU/kg 
rounded to full vials) 
Prescribed doses for prophylaxis infusions higher than approximately 60 IU/kg 
(including  rounding to full vials) have not been studied and therefore are not 
recommended. Rounding to full vials could result in up to 75 IU/kg for some low body 
weights . This is acceptable in children. The dose/kg decreases with increase in 
weight.  
All treatment decisions for identifying the appropriate prophylactic treatment regimen 
should be guided by [CONTACT_266932]’s characteristics 
and treatment response.  
Bleeds will be treated with BAY 94 -9027 as per the investigator’s instruction.  The 
appropriate treat ment of bleeding events is left to the discretion of the treating 
physician, local clinical practice, and may be extrapolated from published guidelines 
(e.g.,  World Federation of Hemophilia [WFH], International Society on Thrombosis 
and Haemostasis [ISTH],  World Health Organization [WHO]). 
The dose for prophylaxis and bleeding will be rounded up to the available vial size. If 
rounding up is not acceptable, rounding down is possible according to investigator 
discretion.  
Type  Biologic 
Route of 
Administration  Intravenous (IV) infusion delivered over 1 to 15 minutes, according to total volume. It 
is recommended to use a peripheral venous access. If a participant has a central 
venous access device ( CVAD), the use of this device is allowed, but a peripheral 
access should be evaluated  and is preferred for the study intervention. 
Participants or caregivers should only self -infuse if they have been trained by [CONTACT_266933]. Participants may only self -infuse under 
supervision of their caregiver. 
Use Experimental 
Unit Dose Strength 500 IU/vial, 1000 IU/vial 
Packaging and 
Labeling  Packaging and Labeling:  
Study intervention will be provi ded as lyophilized powder in a glass vial. Each glass 
vial will be provided with a pre filled syringe of the appropriate amount of sterile ‘’water 
for injection’, European Pharmacopoeia and US Pharmacopeia, for reconstitution. 
Each glass vial will be labeled as required per country requirement.   
[Current/Former 
Name(s) or 
Alias(es)] Commercial name: [CONTACT_266957]® / BAY 94-9027 
For each of the prophylaxis regimens, participants should adhere as closely as possible to the 
assigned dosing frequency.  The day of treatment may vary within ±[ADDRESS_324838] of care, using readily available factor products. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324839] manufactured by [CONTACT_266934] A including patients in  age group < 12 years of age. 
The medical devices provided by [CONTACT_266935]: 
x Vial adapter 
x Prefilled syringe containing sterile Water for Injection  
x Administration set 
In case device deficiencies occur (including  malfunction, use error and inadequate labeling) 
this shall be documented and reported by [CONTACT_266936] (see Section 8.3.10) and appropriately managed by [CONTACT_456]. 
6.2 Preparation, Handling, Storage, and Accountability 
Instructions for the preparation of the study intervention according to the current approved 
Jivi® prescribing information will be provided to the participants. 
1. The investigator or designee must confirm  appropriate temperat ure conditions have 
been maintained during transit for all study intervention received and any 
discrepancies are reported and resolved before use of the study intervention. 
2. Only eligible participants may receive study intervention and only authorized site staff 
may supply or administer study intervention. All study intervention must be stored in a 
secure, environmentally control led, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator 
and authorized site staff. 
3. The investigator or the head of the institution (where applicable) is responsible for 
study intervention accountability, reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records). 
4. Further guidance and information for the final disposition of unused study 
interventions are provided in a separate document.   
In accordance with the approved BAY 94-[ADDRESS_324840] be stored under 
refrigeration (+2°C to +8°C) at the site until dispensing.  Freezing must be avoided.   
At participants’ homes, BAY 94-[ADDRESS_324841] be stored under refrigeration (+2°C to +8°C) or 
may be stored for a single period of up to 6 months at temperatures up to +25°C or 77°F.  
Freezing must be avoided.    
Reconstituted concentrate should be infused  promptly (within 3 hours of reconstitution). 
Parents/caregivers will be provided with detailed instructions for proper storage of the study intervention at home. 
6.3 Measures to Minimize Bias: Randomization and Blinding 
Not applicable. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  27 of 69 
 
6.4 Study Intervention Compliance 
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and electronic case report 
forms (eCRFs). 
When participants are dosed at home, the information will be recorded in EPD 
(see Section 8.1).  Data on infusions for prophylaxis and treatment of bleeds will be collected. 
The parent/caregiver will interact with the i nvestigator or delegate to verify and complete the 
EPD entries. 
Data on the EPD will be transmitted after each  treatment or bleeding event is entered. The 
EPD data will be used to assess compliance with the prophylaxis treatment schedule and with 
the recording of all treatments and bleeding events, and to support the documentation of the 
study intervention inventory.  
Participation in the study may be terminated at th e sponsor's discretion if a participant fails to 
comply with the above protocol requirements. 
All used and unused vials of study intervention must be returned to the study center at each 
study visit. At the end of the study, all used and unused study intervention vials will be counted by [CONTACT_456]’s representative for final drug accountability.  
6.5 Dose Modification 
See Table 6 –1 (Section 6.1) for potential dose modifications. 
6.[ADDRESS_324842] access to the study intervention. 
Subsequent treatment will be mutually agreed upon by [CONTACT_7903]/caregivers and the investigator.  
6.[ADDRESS_324843] the sponsor immediately. Decisions regarding dose interruptions or modifications will be made by [CONTACT_266937]. The participant has to be 
closely monitored for any AE/SAE and laboratory abnormalities. 
6.8 Concomitant Therapy 
Any medication (including over-the-counter or  prescription medicines, recreational drugs, 
vitamins, and/or herbal supplements) or other specific categories of interest that the 
participant received within [ADDRESS_324844] be recorded along with: 
x Reason for use 
x Dates of administration including start and end dates 
x Dosage information including dose and frequency 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  28 of 69 
 
History of vaccinations received within 2 years of study enrollment (including vaccinations for COVID-19) should be collected for all participants. 
Prior use of pegylated medications (e.g., PEG-  interferon, PEG-anti-tumor necrosis factor 
[TNF], PEG-vaccine) will be collected for all participants. 
The Medical Monitor should be contact[CONTACT_88451] e are any questions regarding concomitant or 
prior therapy. 
Bleeds which occur during the screening period through ED 4 will be treated with the 
participant’s own FVIII product. Thereafter, BAY 94 -9027 will be used as the sole FVIII 
source for on-demand treatment of bleeds. In situations with a very low local recovery (see Section [IP_ADDRESS]  for decreased recovery definition) after ED 1 through ED 4, study participants 
may administer their previous FVIII drug at home. 
Pre-medications to tolerate treatment with BAY 94-9027 are not allowed. The use of topi[INVESTIGATOR_266902].   
No other experimental drugs may be taken during the participation in this study.  No immunosuppressive/immunomodulatory drugs may be taken during the study.  If such 
therapy is deemed necessary for the participant ’s welfare, or due to pre -existing illness, the 
situation should be discussed with the sponsor before enrollment. Medications which cause a bleeding diathesis (for example, acetylsalicyl ic acid) are contraindicated in any individual 
with hemophilia and should be avoided, except as  specifically prescribed by a treating 
physician. Use of non-steroidal anti-inflam matory drugs, cyclooxygenase-2 (COX-2) 
inhibitors, or brief courses of corticosteroids to treat pain or acute synovitis, or inhaled or 
topi[INVESTIGATOR_266903] (as for the treat ment of asthma or eczema) are allowed if 
specifically prescribed by a treating physician.  
6.8.1 Rescue Medicine 
In the event of an AESI leading to discontinuati on of study intervention, the participant will 
switch back to his previous FVIII medication. 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1 Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued, the participant will not remain 
in the study. See the SoA (Section 1.3) for data to be collected at the time of discontinuation 
of study intervention and follow up and for any further evaluations that need to be completed. 
Additional participants may be enrolled in the event of treatment discontinuation during the 
first 4 EDs of Part A for reasons other than AESI. 
A participant will be withdrawn from the study and/or study intervention in the following 
cases: 
x A positive inhibitor result at  Baseline visit (Visit 2) 
x At the request of the sponsor 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324845] to treat 
bleeds 
x Development of an inhibitory antibody to FVII I that neutralizes activity sufficiently to 
interfere with effective treatment or require s use of a by[CONTACT_266938] 
x Lack of response to treatment (other than due to an inhibitor) 
x Anaphylaxis or severe hypersensitivity reaction (CTCAE version 5.0, Grade 3 or 
greater) associated with use of BAY 94-9027. See Section 10.1.[ADDRESS_324846] for the treatment of bleeding (e.g., in an emergency) will not 
result in mandatory withdrawal of the participant. 
Prolonged periods >14 days or repeated breaks  in the prophylaxis schedule should be avoided 
and could result in the study partic ipant being removed from the study. 
7.2 Participant Discontinuation/Withdrawal from the Study 
The legal guardian and the pediatric participant have the right to withdraw permission 
(consent or assent, respectively) at any time during the study. If the study staff identify any 
reluctance in the legal guardian or pediatric participant (e.g., signs of verbal or physical 
dissent) about continued participation in th e study, the pediatric participant’s continuation in 
the study should be reevaluated. The same prin ciples that govern permission/assent/consent 
also govern its withdrawal.   
A participant will be withdrawn from the study for any of the following reasons: 
x Withdrawal of consent or assent if applicab le (A pediatric participant’s dissent should 
be respected.) 
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted, as shown in the SoA. See SoA (Section 1.3) for data to be collected at the time 
of study discontinuation and follow up and for any further evaluations that need to be 
completed. 
The participant will be permanently discontinued from the study intervention and the study at 
that time. 
If the participant/parent/legal guardian w ithdraws consent for disclosure of future information, 
the sponsor may retain and continue to use any data collected before such a withdrawal of 
consent. 
7.[ADDRESS_324847] be taken if a partic ipant fails to return to the clinic for a required 
study visit: 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324848] the par ticipant and reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the 
assigned visit schedule, and ascertain wh ether the participant wishes to and/or 
should continue in the study. 
x Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, by 
[CONTACT_21646], and if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent me thods). These contact [CONTACT_19425]’s medical record.  
x Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study. 
8. Study Assessments and Procedures  
x Study procedures and their timing are summarized in the SoA (Section 1.3). Protocol 
waivers or exemptions are not allowed. 
x Immediate safety concerns should be di scussed with the sponsor immediately upon 
occurrence or awareness to determine if th e participant should continue or discontinue 
study intervention. 
x Adherence to the study design requirements, including those specified in the SoA 
(Section 1.3), is essential and required for study conduct. 
x All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
x Procedures conducted as part of the par ticipant’s routine clinical management ( e.g., 
blood count) and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol-specified criteria and were 
performed within the timeframe defined in the SoA. 
8.1 Efficacy Assessments  
Planned timepoints for all efficacy assessments are provided in the SoA (Section 1.3). 
Efficacy endpoints (bleeding epi[INVESTIGATOR_266904] Y 94-9027 consumption) will be collected in 
the EPD. Parents/caregivers or participants, if in tellectual status allows, will be provided with 
EPDs for the entire study and will be trained in the use of the device. Investigators or their 
delegate will interact with parents/caregivers or  participants on a regularly scheduled basis to 
verify the data on the EPD for accuracy and completion.  Thus, the EPD will be considered 
the primary source for these data. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324849] be captured in either the eCRFs or in 
the EPDs, but not both. Information should not be duplicated. 
The following guidance should be used for clar ification of whether the information should be 
recorded in the EPDs or in the eCRFs: 
x All use of study intervention outside the hosp ital/clinic should be recorded in the EPD.  
x Use of study intervention in the hospi[INVESTIGATOR_307]/cli nic as defined in the protocol (e.g., at 
protocol-defined visits for FVIII recove ry) or during an emergency major surgery 
should be recorded in the eCRFs.  
- In the extremely unlikely event that an infusion at a protocol-defined visit is given 
for a bleed, the information should be recorded in the EPD rather than the eCRFs, 
since additional information needs to be collected for bleeding that is not collected in eCRFs.  
- Regular prophylaxis infusions that are not defined in the protocol as being 
administered in the hospi[INVESTIGATOR_307]/clinic at a specif ic visit should be recorded in the EPD 
regardless of whether they are administered in the hospi[INVESTIGATOR_307]/clinic (e.g., infusion information for a participant whose infusion would have been given at home but had to be given in the hospi[INVESTIGATOR_266905]).  
Information recorded in the EPD will include:
 
x Date and time 
x Vial numbers / number of vials and units administered 
x Reason for treatment  
- Prophylaxis 
- Spontaneous bleed first treatment 
- Trauma bleed first treatment 
- Minor surgery  
- Follow-up treatment 
- Unscheduled/preventative prophylaxis (for physical activities, suspected or 
non-evident bleeding following identified trauma) 
8.1.[ADDRESS_324850] dose of study intervention (regardless if treated or 
not, or treated at home or under medical supervision) as well as any potential treatment with other hemophilia drugs will be recorded in the EPD: 
x Date and time of onset 
x Type of bleeding (spontaneous, trauma, join t, muscle, skin/mucosal, internal, other) 
x Location 
x Intensity (mild, moderate, severe) 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  32 of 69 
 
x Treated (yes/no): 
 If “yes”: Date and time  
 Product used: Study intervention / other drug 
 Doses 
If BAY 94-9027 is used for the treatment of a bleeding epi[INVESTIGATOR_1865], the response to treatment 
(excellent, good, moderate, poor, or none).   
For guidance to the participants’ parents/caregivers , the following definitions for response to 
treatment are suggested.  Individual responses may vary:  
x Excellent : Abrupt pain relief and /or improvement in signs of bleeding with no 
additional infusion administered   
x Good :  Definite pain relief and/or improvement in signs of bleeding, but possibly 
requiring more than one infusion for complete resolution   
x Moderate :  Probable or slight improvement in signs of bleeding, with at least one 
additional infusion for complete resolution   
x Poor (or None) :  No improvement or condition worsens.   
8.1.3 Clinical Outcome Assessments 
[IP_ADDRESS]  Hemophilia Specific Quality of Life (Haemo-QoL) Questionnaire 
In this study, the Haemo-QoL Short Form Ques tionnaire for children 8-16 years old will be 
used by [CONTACT_266939] 7- <8 years of age.  
The Haemo-QoL Short Form contains 35 questions covering 9 domains: Physical Health, 
View of Yourself, Family, Friends, Othe rs, Sports, Dealing, and Treatment.  
The respondent burden for this questionnaire is approximately 15 minutes. The 
participant/parent/legal guardian will complete the questionnaire and the data will be entered 
in eCRF by [CONTACT_266940].  
[IP_ADDRESS]  Patient/Caregiver Global Impression of Severity and Change 
These 4 instruments are made of one single-item measure. They will explore 
patient--perceived and caregiver-perceived overall severity and change in health status since 
the start of study intervention. These instruments will be used to anchor the scores of Haemo-QoL. The participant/parent/legal gua rdian will complete the questionnaire and the 
data will be entered in eCRF by [CONTACT_266940].  
The respondent burden for both questionnaires is approximately 2 minutes.  
8.2 Safety Assessments  
The safety assessments for the study include: 
x (S)AEs, including AESI, AEs leading to disc ontinuation of study intervention (Section 
[IP_ADDRESS]  ) 
x FVIII inhibitor development using the Nijmegen-modified Bethesda assay. The first 
positive inhibitor test after a participant has started treatment with study drug will be 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  33 of 69 
 
confirmed by [CONTACT_6310] a second (separately dr awn) sample in a central laboratory. 
(Section 8.3.9 ) 
x Anti-drug antibodies 
x Physical examination findings, vital si gns and laboratory values (Section 8.2.1  to 
8.2.3 ) 
x Evaluation of concomitant medication (Section 6.8) 
x Long-term safety assessments: 
o Quantitative PEG measurement 
o Liver enzymes  
o Urine and serum biomarkers  
o Neurological assessment.  
Planned time points for all safety assessments are provided in the SoA (Section 1.3). 
Clinically significant abnormal findings will be reported as AEs in the eCRF 
8.2.1 Physical Examinations 
A complete physical examination will include a review of body systems, and measurement of 
body height (cm), and weight (kg).   
Standard neurological assessment will be performed by [CONTACT_093] (neurologist not 
required) at the timepoints indicated in the SoA (Section 1.3).  
8.2.2 Vital Signs 
Measurement of vital signs will include: systol ic and diastolic blood pressure, heart rate, and 
body temperature. Vital signs will be measur ed before and after administration of study 
intervention at time points i ndicated in the SoA (Section 1.3).   
8.2.[ADDRESS_324851] of clinical laboratory tests to be performed and the SoA 
(Section 1.3) for the timing and frequency.  
x The investigator must review the laboratory report, document this review, and 
record any clinically significant changes occurring during the study as an AE. The 
laboratory reports must be filed with the source documents.  
x Abnormal laboratory findings associated with the underlying disease are not 
considered clinically significant unless judged by [CONTACT_266941]'s condition. 
x All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_324852] dose of study intervention 
should be repeated until the values ret urn to normal or baseline or are no longer 
considered clinically significant by [CONTACT_266942]. 
x If clinically significant values do not return to normal/baseline within a 
period of time judged reasonable by [CONTACT_093], the etiology should be 
identified, and the sponsor notified. 
x All protocol-required laboratory tests, as defined in Section 10.2, must be 
conducted in accordance with the laboratory manual and the SoA.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  34 of 69 
 
x If laboratory values from non-protocol-specified laboratory tests performed 
at the institution’s local laboratory  require a change in participant 
management or are considered clinically significant by [CONTACT_093] 
(e.g., SAE or AE or dose modification), then the results must be recorded. 
[IP_ADDRESS]  Decreased recovery 
In the event that recovery is lower than expected based on local FVIII post-infusion levels 
after the first infusions (e.g., recovery of <1.2 kg/dL):  
x Increase dose to 60 IU/kg, and/or  
x Additional prophylaxis infusion may be added  
x Assess response to treatment with local assessment of recoveries, post-infusion 
levels 
In patients with positive anti-PEG ADAs, obtain the following weekly until antibody 
titers are declining and FVIII recovery is stable.  
x  One each for both local and central lab:  
o Pre-infusion FVIII blood/plasma samples  
o FVIII blood/plasma samples 15-[ADDRESS_324853] infusion for recovery 
x One for central lab: 
o Blood/plasma sample for anti-PEG IgM  
Once antibody titers are declining and FVIII recovery is stable, assess FVIII recovery 
and ADA monthly until ADAs disappear. 
For study participants that have discontinued study drug, FVIII inhibitor tests must be done 
after a sufficient wash-out period depending on the FVIII product the participant is receiving – at least 48 hours or 72 hours for SHL and EHL FVIII products respectively 
 
8.3 Adverse Events (AEs), Serious Adverse Events (SAEs) and Other Safety 
Reporting 
The definitions of adverse events (AEs) and SAEs can be found in Section 10.3. 
AEs will be reported by [CONTACT_2299] (or, when  appropriate, by a caregiver, surrogate, or the 
participant's legal guardian). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up all AEs including AEs that are serious, considered related to the study 
intervention or study procedures, or that caus ed the participant to discontinue the study 
intervention (see Section 7). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitti ng SAE reports are provided in Section 10.3. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  35 of 69 
 
8.3.1 Time Period and Frequency for Collecting AE and SAE Information  
(S)AEs (including AESI) will be collected f rom the start of study intervention until the last 
visit at the timepoints specified in the SoA (Section 1.3). (S)AEs which are related to 
protocol-required study procedures, e.g., (S)AE related to invasive study procedures will be 
recorded as (S)AEs from the signing of the ICF. 
Any medical occurrences/conditions that begin in the period between signing ICF and the 
start of study intervention, and which are not re lated to a protocol-required study procedure, 
will be recorded as medical history/ current medical conditions, not as AEs. 
All SAEs and AESIs will be recorded and repo rted to the sponsor or designee immediately 
and under no circumstance should this exceed 24 hours of learning of the event, as indicated 
in Section 10.3. The investigator will submit any updated SAE data to the sponsor within 24 
hours of it being available. 
Investigators are not obligated to actively seek information on AEs or SAEs after conclusion 
of the study participation. However, if the investigator learns of any SAE, including a death, 
at any time after a participant has been discharg ed from the study, and he/she considers the 
event to be reasonably related to the study inte rvention or study participation, the investigator 
must promptly notify the sponsor.  
 
8.3.2 Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences. 
Clinical Presentation of Adverse Events 
Study site staff should instruct the legal gua rdians and caregivers on how to report signs and 
symptoms (e.g., crying and pain) in the indi vidual pediatric participant. They will be 
instructed to report both specific and non-speci fic symptoms (including vomiting, diarrhea, 
sleepi[INVESTIGATOR_008], variation in the intensity, etc.). These non-specific symptoms may be the only 
manifestations of some adverse reactions observed in children. Care should be taken that the 
clinical presentation of adverse reactions is not  misinterpreted as the manifestation of a pre-
existing or unrelated condition. 
Moreover, symptoms that are dependent on participant communication ability (e.g., nausea, 
pain, mood alterations) in younger or mentally di sabled children could potentially be at risk 
for under- or mis-reporting. 
8.3.3 Follow Up of AEs and SAEs 
After the initial AE/SAE report, the investig ator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs, and AESI (as defined in Section 8.3.8 ), 
will be followed until resolution, stabilizati on, the event is otherwise explained, or the 
participant is lost to follow up (as defined in Section 7.3). Further information on follow-up 
procedures is provided in Section 10.3.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324854] the safety of participants and 
the safety of a study intervention under clinical investigation are met.  
x The sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under clinical 
investigation. The sponsor will comply with country-specific regulatory 
requirements relating to safety reporting to the regulatory authority, institutional 
review boards (IRBs)/inde pendent ethics committees (IECs), and investigators. 
x An investigator who receives an investigator safety report describing an SAE or 
other specific safety information (e.g., summary or listing of SAEs) from the 
sponsor will review and then file it along with the IB and will notify the IRB/IEC, 
if appropriate according to local requirements. 
x For all studies except those using medical devices, investigator safety reports must 
be prepared for S[LOCATION_003]Rs accordi ng to local regulatory requirements and sponsor 
policy and forwarded to investigators as necessary. 
Disease-Related Events and/or Disease-Rel ated Outcomes Not Qualifying as AEs or 
SAEs 
The following disease-related events (DREs) are common in patients with hemophilia A and 
can be serious/life-threatening: 
x Bleeding event 
Any bleeding event occurring during the study will not be documented as an AE, because this 
is captured in the assessment of efficacy. Because  these events are typi[INVESTIGATOR_266906], they will not be reported according to the standard process for expedited reporting of AEs. These events will be recorded in the EPD. 
NOTE: If the bleeding fulfills the criterion for an SAE (e.g., results in hospi[INVESTIGATOR_059]), then 
the event should be recorded and reported as an SAE (Section 10.3.4 ). 
NOTE: If either of the following conditions applies, then the event must be recorded and 
reported as an SAE (instead of a DRE): 
x The event is, in the investigator’s opi[INVESTIGATOR_1649], of greater intensity, frequ ency, or duration 
than expected for the individual participant  
OR 
x The investigator considers that there is a reasonable possibility that the event was 
related to study intervention. 
8.3.5 Pregnancy 
Not applicable in this pediatric male participant population. 
8.3.6 Cardiovascular and Death Events 
Death will be reported with the known cause of death as a SAE.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  37 of 69 
 
8.3.7 Disease-related Events and/or Disease-related Outcomes Not 
Qualifying as AEs or SAEs 
See Section 8.3.[ADDRESS_324855] (AESI)  
The AESI in this study are: 
Hypersensitivity: defined as an immune re action related to the administration of study 
intervention (BAY 94-9027). Hypersensitivity  reactions may also occur in the absence 
of anti-PEG antibodies. It does not include hypersensitivity reactions which are not 
related to drug administration such as but not limited to rash related to contact 
[CONTACT_8748]. 
The first [ADDRESS_324856]. When LoE is suspected, a sample for 
anti-PEG antibodies should be sent to the central lab.  
The following are considered LoE, even in the absence of a bleeding event: 
o Post-infusion FVIII that is not detectable or less than 15% with high titer (1:16 
or greater) PEG IgM antibodies 
o Recovery is insufficient due to anti-PEG IgM antibodies to maintain FVIII 
concentrations via modification of the dose and/or dosing interval to maintain adequate prophylaxis against bleeding  
A reduced recovery/post-infusion FVIII level is not  considered LoE if adequate 
prophylaxis can be achieved with an incr eased dose and/or decreased interval 
(generally, recovery >0.5 kg/dL). 
The following information needs to be included on the eCRFs: time point of AESI in relation 
to administered study intervention, cumulati ve number of infusions of study intervention 
received as of time of adverse event, causal relation, duration, severity, symptoms, concomitant symptoms/disease, treatment, va ccination and time point, outcome, and history 
of previous allergic reactions.  
[IP_ADDRESS]  Clinical guidance for hypersensitivity reactions requiring treatment 
A: In the event of a hypersensitivity reacti on occurring at the study site, while study 
participant is under medical supervis ion, the following is to be done: 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324857] of 
care/guidelines 
2. Further observation for 1 hour after resolution of symptoms 
3. Obtain  
a. Two blood/plasma samples each for FVII I level, and FVIII inhibitor (1 for 
local lab and one for central lab. Note : sample for FVIII inhibitor can be 
omitted if already collected prior to infusion of study intervention as per SoA (Section 1.3 SoA)), AND 
b. One blood/plasma sample for anti -PEG , anti-PEG IgM and IgE (only for the 
central lab).   
4. Discontinue study intervention and resume prophylaxis treatment with prior FVIII 
product. 
5. Schedule a follow-up visit (early discontinuati on visit) within 4 weeks after the event  
a. For assessment of general well- being of the study participant 
b. To perform assessments for early discont inuation of study participation as per 
SoA (Section 1.3 SoA) including evaluation of FVIII inhibitor and anti-PEG, 
anti-PEG IgM, IgE (only for the cent ral lab) and excluding factor VIII 
recovery
 and in-hospi[INVESTIGATOR_266907].   
B: If the event of a hypersensitivity reaction occurring while study participant is not under 
medical supervision at study site (e.g., at home), the following is to be done: 
1. Participants should seek prompt medical attention in case of occurrence of any 
symptom of hypersensitivity reactions and inform the investigator or site staff.   
If treatment of hypersensitivity reaction occurs at the study site, then follow the steps 
outlined in in “A” above. 
If treatment of hypersensitivity reaction occurs outside the study site, then follow the 
steps below: 
2. Discontinue study intervention and resume prophylaxis treatment with prior FVIII 
product  
3. Schedule a visit to the study site within 4 days of the reported event for  
a. Assessment of general well- being of the study participant 
b. AE review.  
At this visit obtain:  
c. Two blood/plasma samples each for FVIII level and FVIII inhibitor (1 
for local lab and one for central lab), AND 
d. One blood/plasma sample for anti-P EG, anti-PEG IgM and IgE (only for 
the central lab)  
4. Schedule a second follow-up visit (early  discontinuation visit) approx. [ADDRESS_324858] visit (see step 3)  
a. For assessment of general well- being of the study participant, AND 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  39 of 69 
 
b. Perform assessments for early discontinuation of study participation as 
per SoA (Section 1.3 SoA) including evaluation of FVIII inhibitor and 
anti-PEG, anti-PEG IgM, IgE (only for the central lab) and excluding 
factor VIII recovery and in-hospi[INVESTIGATOR_266907].  
For study participants that have discontinued study drug, FVIII level and FVIII inhibitor tests 
must be done after a sufficient wash-out  period depending on the FVIII product the 
participant is receiving – at least 48 hours or 72 hours for SHL and EHL FVIII products 
respectively. 
[IP_ADDRESS]  Clinical guidance for loss of efficacy (LoE) 
LoE is defined in Section 8.3.8 .  
In the event of reported LoE of the study intervention, the following is to be done: 
1. Schedule a visit within 4 days of the reported event  
2. Obtain  
a. Two pre-infusion blood/plasma samples each for FVIII level and FVIII 
inhibitor (1 for local lab a nd one for central lab), AND 
b. One blood/plasma sample for anti-PEG a nd anti-PEG IgM (for the central lab) 
3. Administer BAY 94-9027 (use current prophylaxis dose (IU/kg)) 
4. Obtain  
a. Two post-infusion blood/plasma samples (1 for local lab and one for central 
lab) for FVIII level (15-[ADDRESS_324859]-infusion)  
5. Discontinue study intervention and resume prophylaxis treatment with prior FVIII 
product if LoE is confirmed by [CONTACT_266943]-infusion FVIII levels. Inform and discuss with sponsor. 
6. Schedule a second follow-up visit (early di scontinuation visit) approx. [ADDRESS_324860] visit (see step 1) 
a. For assessment of general well- being of the study participant 
b. Perform assessments for early disconti nuation of study participation as per 
SoA (Section 1.3 SoA) including evaluation of FVIII inhibitor and anti-PEG, 
anti-PEG IgM (only for the central lab) and excluding factor VIII recovery and in-hospi[INVESTIGATOR_266907].  
 
[IP_ADDRESS]  Assessment of Severity of AESI 
All AESIs will be graded for severity according to CTCAE version 5.0. If no exact matching 
code is available in CTCAE version 5.0, then use the following guide: 
Grade refers to the severity of the AESI. The CTCAE displays Grades 1 through 5 with 
unique clinical descriptions of severity for each AE based on this general guideline: 
x Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated 
x Grade 2  Moderate; minimal, local, or noninvasi ve intervention indicated; limiting 
age-appropriate instrumental activities of daily living (ADL)* 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  40 of 69 
 
x Grade 3  Severe or medically significant but  not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self care ADL** 
x Grade 4  Life-threatening consequences; urgent intervention indicated 
x Grade 5  Death related to AE 
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_43240] r groceries or clothes, using the telephone, managing 
money, etc. 
**Self care ADL refer to bathing, dressing, and undres sing, feeding self, using the toilet, taking medications, 
and not bedridden. 
Immune System Disorders 
CTCAE 
term  Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Allergic 
reaction  Systemic 
intervention 
not 
indicated Oral 
intervention 
indicated Bronchospasm; 
hospi[INVESTIGATOR_266908]; intravenous 
intervention indicated  Life-threatening 
consequences; 
urgent intervention 
indicated   Death 
Definition : A disorder characterized by [CONTACT_221742].  
Navigational note : If related to infusion, use injury, poisoning and procedural complications: Infusion related 
reaction. Do not report both.  
Anaphylaxis - - Symptomatic bronchospasm, 
with or without urticaria; 
paren teral intervention 
indicated; allergy -related 
edema/angioedema; 
hypotension  Life-threatening 
consequences; 
urgent intervention 
indicated  Death 
Definition : A disorder characterized by [CONTACT_210938]-like substances from mast cells, caus ing a hypersensitivity immune response. Clinically, it 
presents with breathing difficulty, dizziness, hypotension, cyanosis, and loss of consciousness and may lead to 
death.  
Source: Common Terminology Criteria for Adverse Event s (CTCAE), v 5.0, published November 27, 2017), US 
Department of Health and Human Services  
 
8.3.9 Other Important Events  
Anti-drug antibody development 
All subjects will be tested for the development of anti-drug antibodies (anti- PEG and anti-
PEG IgM). Binding antibodies to PEG will be analyzed in an enzyme-linked immunoassay 
(ELISA). 
In participants who experience LoE, neutralization of activity of BAY 94-9027, observed as 
lower than expected FVIII recovery, a blood sample should be obtained to test for ADAs 
(Section [IP_ADDRESS] ).  
IgE will be analyzed in participants who experience hypersensitivity reactions due to 
development of ADA.   
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324861] is defined with a threshold of ≥ 0.6 BU/mL at the central laboratory. If 
an inhibitor to FVIII is detected after the participant has started treatment with study intervention, the investigator will be notified, and repeat testing within [ADDRESS_324862] 
technical complaint (PTC) form and submitting the information via the ePTC form or by 
[CONTACT_266944] [EMAIL_5180].  
NOTE: Deficiencies fulfilling the definition of an AE/SAE will follow the processes outlined 
in Section 10.4 of the protocol.  
8.4 Pharmacokinetics 
Detailed PK analysis will not be performed, but FVIII recovery will be assessed frequently as 
per SoA (Section 1.3).  
8.5 Genetics 
Genetics are not evaluated in this study. 
8.6 Biomarkers 
Serum and urinary biomarkers will be measu red for assessment of renal safety (Section 10.2). 
A limited amount of blood is collected; any remaining amount may be used for additional 
research on study intervention and/or disease understanding. Blood volume will not be increased for these research purposes. 
In addition, further investigations related to the mode of action or the safety of BAY 94-9027 
and similar drugs for the treatment of hemophi lia may be performed. The same applies to 
further investigations deemed relevant to he matological diseases and associated health 
problems. Examples of these investigations in clude diagnostic, safety, pharmacodynamic, 
monitoring, or potentially predictive biomarkers. 
Results from any additional investigations may be reported separately.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324863] important 
endpoints including primary and key secondary endpoints. 
9.1 Statistical Hypotheses 
Hypothesis testing is not planned for this study.  Based on a Bayesian analysis for the primary 
endpoint, the posterior probability that the true  incidence for an AESI is <5% will be 
estimated. 
9.2 Analysis Sets 
Participant Analysis Set  Description  
Safety anal ysis set 
(SAF Part A)  A participant will be included in the SAF part A if he is enrolled into the part A of 
the study and has taken at least 1 dose of the study intervention. 
Modified Safety 
analysis set (mSAF Part A)
 A participant will be included in the  mSAF part A if he is enrolled into the part A 
of the study and has taken up to 4 doses of the study intervention and does not 
discontinue study for other reason than an AESI before the fourth ED 
regardless of emergency use of other FVIII medication . 
Modified Intent -to-treat 
analysis set (mITT Part A) A participant will be included in the mITT part A if he is enrolled into the part A 
of the study, has taken at least 1 dose of the study intervention, and has 
subsequent data for infusions/bleeds document ed in the EPD. 
Safety analysis set (SAF 
Part B)  A participant will be included in the SAF part B if he is enrolled into the part B of 
the study and has taken at least 1 dose of the study intervention in Part B. 
Modified i ntent-to-treat 
analysis set ( mITT Part B) A participant will be included in the mITT part B if he is enrolled into the part B 
of the study, has taken at least 1 dose of the study intervention in Part B , and 
has subsequent  data for infusions/bleeds documented in the EPD 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  43 of 69 
 
9.3 Statistical Analyses 
9.3.1 General Considerations 
Descriptive statistics will be used for all s tatistical analyses. The pr imary endpoint will be 
analyzed for part A. Secondary endpoints for the primary and secondary  objectives will be 
analyzed for parts A, and B. More details will be provided in the statistical analysis plan. 
Assessment of safety will be performed based on the safety analysis set.  
Assessment of efficacy will be performed based on the modified ITT analysis set.  
9.3.2 Primary Endpoint(s)/Estimand(s) Analysis 
See Section 3 for a description of the primary endpoint and estimand. 
The mSAF for part A analysis set will be used in this analysis, see Section 9.2. As described 
in Section 3, the primary estimand targets the stratum of participants who do not discontinue 
treatment with BAY 94-9027 for other reason than  an AESI before the fourth ED regardless 
of emergency use of other FVIII medication.  
Due to the expected low incidence of AESIs ( Santagostino et al. 2020 ), a Bayesian approach 
will be used for analysis of the primary endpoint.  
The 25 participants from age group 7 to <[ADDRESS_324864] KIDS study with 0 AESIs 
will be combined with the n participants and AESIs from this study for the analysis of the 
probability of an AESI ( p), with a total observed sample size of 25 + n = N. The Bayesian 
model for the analysis is then specified as follows: 
 r i ~ Bernoulli ( p): occurrence of an AESI in participant i , i = 1,… , N;  
            p ~ Beta(1/4,1/4); prior for the probability of an AESI. G
The choice of the neutral prior Beta (1/4,1/4) is  to avoid over influence of the prior and limit 
the degree of polarization of the prior toward 0 and 1. The posterior distribution based on the 
pooled data will then be Beta(x+1/4,N-x+1/4), where x is the number of participants in the pooled data who experience an AESI.  
To note, the above analysis by [CONTACT_266945] [ADDRESS_324865] KIDS prior 
to the Bayesian analysis is equivalent to treating the 25 participants with 0 AESIs as historical data and updating the initial prior Beta(1/4,1/4) to be Beta(0+1/4,25+1/4) as the updated prior for the analysis of participants from this study alone. 
The safety of BAY 94-9027 will be characteriz ed by [CONTACT_266946], including its mean, median, mode, and 90% two-sided credible 
intervals. The posterior probability that the incidence of AESI is <5% will be derived.  
9.3.3 Secondary Endpoint(s)/Estimand(s) Analysis  
[IP_ADDRESS]  Analysis of Secondary Endpoints for the Primary Objective 
To further address the primary objective, the fo llowing secondary endpoints will be analyzed: 
x Adverse drug reactions (ADRs) 
x Anti-drug antibody (ADA) development 
x Inhibitor development 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  44 of 69 
 
The analyses for these 3 endpoints will be base d on the SAF part A and SAF part B analysis 
sets, see Section 9.2 for details. 
Adverse drug reactions The number and proportion of participants with any ADRs will be presented.  Anti-drug antibody response The number and proportion of participants with anti-drug antibodies will be presented along 
with by-participant listings for ADA responses. 
Inhibitor development The number and proportion of participants with co nfirmed FVIII inhibitors will be presented 
by [CONTACT_15247] (low titer: < 5 BU/mL , high titer: ≥ 5 BU/mL) along with by-participant listings for all 
measurements of FVIII inhibitors. Note that only inhibitors confirmed by a second positive measurement will be considered positive in the analysis, see Section 8.3.9 . The listing will 
show all results. 
[IP_ADDRESS]  Analysis of Secondary Endpoints for the Secondary Objective 
To address the secondary objective, the follow ing secondary endpoints will be analyzed. 
x Number of bleeds per individual obser vation period of continuous prophylactic 
treatment to assess (annualized) bleeding rates  
x BAY 94-9027 consumption  
x Number of infusions/month and year (Annualized Infusion Rate) 
The analyses for these [ADDRESS_324866] 3 months without development of an inhibitory antibody to FVII I or ADA that neutralizes activity sufficiently 
to interfere with effective treatment. The subset of participants in the modified ITT analysis set fulfilling this condition will be used for estimation. 
For each participant, the number of bleeds will  be related to the individual observation period 
to assess bleeding rates. Bleeding rates will be annualized at the individual participant level using the formula: 
ABR = (number of bleeds * 365.25)/(the available period in the study in days). 
Descriptive statistics (N, mean, median, standard deviation, range, Q1, and Q3) will be used 
to summarize the derived annualized bleeding rates on a group level .  
ABRs will be presented for the following types of bleedings: 
- Annualized total bleeding (sum of spontaneous bleeds and trauma bleeds) rate 
- Annualized spontaneous bleeding rate 
- Annualized trauma bleeding rate 
- Annualized joint bleeding rate 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  45 of 69 
 
In addition, model-based estimates for the bleedi ng rates will be derived using a Negative 
Binomial model, where ݕ௜ denotes the number of bleeding epi[INVESTIGATOR_266909] ݐ௜ (possibly differing time periods of follow ‐up) for participant ݅ǡ݅ ൌͳǡǥǡ݊  . Assume 
that ܻ௜ follows a Negative Binomial distribution with mean ߤ௜ and a common dispersion 
parameter ߙ .Then ߤ௜ can be modeled as 
ߤ௜ൌ  ݐ ௜൅ߚ଴ǡ 
We thus have 
ߤ௜ൌ  ݐ ௜൅ߚ଴֞ఓ೔
௧೔ൌ  ሺߚ଴ሻǤ  
With an estimate for the parameter ߚ଴ the mean rates of events per time unit can be estimated 
via ሺߚ଴ሻ. This estimate will be provided with its 95% confidence interval. 
Determination of Bleeding Count: 
Bleeds occurring on the same calendar day will be counted as one bleeding epi[INVESTIGATOR_266910]. A spontaneous joint or spontaneous muscle bleed reported within 72 hours after an identical bleed at the same site or infusion for such a bleed will not be counted as new bleed. Infusions for such bleeds will be considered to be follow-up infusions. (Srivastava et al. 2020 )  
BAY 94-9027 consumption  
Summary statistics for BAY 94-9027 consumpt ion will be provided for prophylaxis 
treatment, for treatment of bleeds, and overall. Consumption per year and per infusion will be 
presented based on total dose (IU) and dose per body weight (IU/kg).  
Number of infusions/month and ye ar (Annualized Infusion Rate) 
Descriptive statistics (N, mean, median, sta ndard deviation, range, Q1, and Q3) for the 
number of infusions, number of infusions per month, and annualized infusion rate will be presented. 
9.[ADDRESS_324867] 6 
months of Part B. A final analysis w ill be done at the end of the study.  
9.5 Sample Size Determination 
The selection of the sample size of 30 is based on the assumption that less than 5% of 
participant out of 30 will experience an AESI  and that the data will be pooled with 25 
participants from the age group of 7 to <12 years of study [ZIP_CODE] (PROTECT KIDS; [STUDY_ID_REMOVED]) for analysis of the incidence of AESIs. Additional participants may be enrolled in the event of treatment discontinuati on during the first 4 EDs of Part A for reasons 
other than AESI. The study would strive for a balance between age group 7 to <9 years and 
9 to <12 years. 
A Bayesian Beta-binomial model with each participant having an AESI as a Bernoulli 
response and a neutral prior probability distribution Beta (1/4,1/4) is used. The choice of the 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  46 of 69 
 
neutral prior Beta (1/4,1/4) is to avoid over influence of the prior and limit the degree of polarization of the prior toward 0 and 1.  
Under these assumptions, the posterior probability that the true incidence for an AESI is <5% 
will be > 90%.  
Details are described by [CONTACT_266947]:  
x If no participant out of 30 from the new study experience an AESI, then with the 
Bayesian analysis mentioned above, it is ca lculated that the median of the posterior 
distribution of the true incidence of AESI is <0.1% and there is >99% posterior probability that the true incidence of AESI is <5%. 
x If 1 participant out of 30 from the new study experience the AESI, it is calculated by a 
Bayesian Beta-binomial inference with a prior of Beta (1/4,1/4) for the pooled 55 
participants that the median of the posterior distribution of the true incidence of AESI 
is 1.7% and there is 91% posterior probabilit y that the true incidence of AESI is <5%. 
x If 2 participants out of 30 from the new study experience the AESI, then the median of 
the posterior distribution of the true in cidence of AESI is 3.5%, and there is 71% 
posterior probability that the true incidence of AESI is <5%. 
x If 3 participants out of 30 from the new study experience the AESI, then the median of 
the posterior distribution of the true in cidence of AESI is 5.4%, and there is 46% 
posterior probability that the true incidence of AESI is <5%. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  47 of 69 
 
10. Supporting Documentation and Operational Considerations  
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
10.1.1  Regulatory and Ethical Considerations 
 
x This study will be conducted in accordance with the protocol and with the 
following: 
x Consensus ethical principles derived from international guidelines 
including the Declaration of Hels inki and Council for International 
Organizations of Medical Sciences (CIOMS) international ethical 
guidelines 
x Applicable ICH Good Clinical Practice (GCP) guidelines 
x Applicable laws and regulations 
x The protocol, protocol amendments, ICF, IB,  and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_97277]/IEC before the study is initiated.  
x Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary 
to eliminate an immediate hazard to st udy participants. Any substantial 
modification of the protocol will be s ubmitted to the competent authorities as 
substantial amendments for approval, in accordance with ICH GCP and national 
and international regulations. 
x Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants. 
x The investigator will be responsible for the following: 
x Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/IEC 
x Notifying the IRB/IEC of SAEs or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures 
x Providing oversight of the conduct of the study at the site and adherence to 
requirements of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations 
The investigator will be responsible for reporting cases of suspected child abuse and/or 
neglect according to local regulations includi ng local medical association (e.g., American 
Academy of Pediatrics, EU Academy of Pediatrics) or Health Department guidelines. 
10.1.2  Financial Disclosure 
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  48 of 69 
 
10.1.3  Informed Consent and Assent Process 
x The investigator, or a person designated by [CONTACT_093], will provide the legal 
guardian (refer to Appendix 10.4 Abbreviations and Definitions) with the written 
ICF and the participant with the assent if applicable. They must be informed that participation is voluntary. The legal guardian will be required to sign written consent, and the participant if applicable will be required to sign written assent, that meets the requirements of 21 CFR 50, local regulations, International Council on Harmonisation (ICH) guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center after the nature of the study has been fully explained and before performance of any study-related activity. 
x Assent requirements for pe diatric participants may vary across regions and 
countries; local regulations should be follo wed as appropriate.  Assent should be 
obtained from participants, depending on their age and intellectual status and 
according to local practice.  
x The medical record must include a statement that written informed consent from the 
legal guardian and assent from the ped iatric participant (if deemed appropriate by 
[CONTACT_266948]) were obtained before the participant was enrolled in the study and the date the written consent and assent were obtained.  
The authorized person obtaining the informed consent must also sign the ICF and assent form attesting that the pediatric participant did not show signs of dissent particularly in those studies including t oddlers and small children; it should be 
written in language appropriate to the ch ild’s developmental and functional status.  
x Participants and their legal guardian must be re-consented and re-assented to the 
most current version of the ICF(s) during their participation in the study.  
x Minor participants who assent to a study and later withdraw that assent should not 
be maintained in the study against their will, even if their legal guardian still wants them to participate. 
x A copy of the informed consent and assent forms must be provided to the 
participant and the participant’s legal guardian. 
x As appropriate, participants may be given the opportunity to meet privately with a 
member of the site staff to ask confidential questions and to decline assent for 
confidential reasons, which, at their request, would not be shared with their legal guardian, unless required by [CONTACT_1769]. 
x There will be no attempt to recontact [CONTACT_266949]. However, the 
participant retains the right to withdra w assent/consent for storage of samples 
unless specified. 
x Stored samples will be coded throughout the sample storage and analysis process 
and will not be labeled with personal iden tifiers. Participants may withdraw their 
consent/assent for their sample s to be stored for research. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  49 of 69 
 
10.1.4  Data Protection 
x Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records, datasets or biological samples that are transferred to the sponsor will 
contain the identifier only; participant names or any information which would make 
the participant identifiable will not be transferred. 
x The participant must be informed that his/her personal study-related data will be 
used by [CONTACT_10999]. The level of 
disclosure must also be explained to the participant who will be required to give 
consent for their data to be used as described in the informed consent.  
x The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326]. 
10.1.5  Dissemination of Clinical Study Data 
Result Summaries of Bayer's sponsored clinical trials in drug development Phases 2, 3 and 4 
and Phase 1 studies in patients are provided in the Bayer Trial Finder application after 
marketing authorization approval in line w ith the position of the global pharmaceutical 
industry associations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Da tabases". In addition, results of clinical drug 
trials will be provided on the publicly funded website ClinicalTrials.gov and EU Clinical 
Trials Register in line with the applicable regulations. 
Bayer commits to sharing upon request from qu alified scientific and medical researchers 
patient-level clinical trial data, study-level clinical  trial data, and protocols from clinical trials 
in patients for medicines and indications approv ed in the [LOCATION_002] (US) and European 
Union (EU) on or after January 01, 2014, as ne cessary for conducting legitimate research. 
All Bayer-sponsored clinical trials are considered  for publication in the scientific literature 
irrespective of whether the results of the clinical trials are positive or negative. 
 
10.1.6  Data Quality Assurance 
x All participant data relating to the study w ill be recorded on printed or electronic 
CRFs unless transmitted to the sponsor or designee electronically (e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate and 
correct by [CONTACT_1189].  
x Guidance on completion of CRFs will be provided in the eCRF HelpText on the 
CRF and/or the eCRF Completion Instructi ons available online in the electronic 
data capture system. 
x The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
x Monitoring details describing strategy, in cluding definition of study critical data 
items and processes (e.g., risk-based initia tives in operations and quality such as 
risk management and mitigation strategies and analytical risk-based monitoring), 
methods, responsibilities, and requirements , including handling of noncompliance 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  50 of 69 
 
issues and monitoring techniques (centr al, remote, or on-site monitoring) are 
provided in the monitoring plan / contracts. 
x The sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
x The sponsor assumes accountability for actions delegated to other individuals (e.g., 
contract research organizations). 
x Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 15 years after study completion 
unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written 
approval of the sponsor. No records may be transferred to another location or party 
without written notification to the sponsor.  
 
10.1.7  Source Documents 
x Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collec ted. Source documents are filed at the 
investigator’s site.  
x Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must 
be explained. The investigator may need to request previous medical records or 
transfer records, depending on the study. Also, current medical records must be 
available. 
x Definition of what constitutes source data and its origin can be found in the Source 
Data Location List (SDLL) or equivalent. 
x The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
x The sponsor will perform monitoring to confirm that data entered into the CRF by 
[CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of pa rticipants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol 
and any other study agreements, ICH GCP, and all applicable regulatory 
requirements.  
10.1.[ADDRESS_324868] participant is recruited. Study/Site Termination 
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of th e sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study site closure visit has been performed. 
The investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  51 of 69 
 
Reasons for the early closure of a study site by [CONTACT_11004]: 
For study termination: 
x Discontinuation of further study intervention development 
For site termination: 
x Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines 
x Inadequate or no recruitment (evaluate d after a reasonable amount of time) of 
participants by [CONTACT_093] 
x Total number of participants included earlier than expected. 
Stoppi[INVESTIGATOR_266911], the trial will be stopped if any of the following study intervention related events 
occurs: 
x One case of anaphylaxis (CTCAE version 5.0, Grade 3 or higher) or 
x One case of severe hypersensitivity/allergic reaction (CTCAE version 5.0, Grade 3 or 
higher)  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by 
[CONTACT_1214]. The investigator shall promptly inform the participant 
and should assure appropriate therapy and/or follow up. 
10.1.[ADDRESS_324869] editorial and ethi cal practice, the sponsor will generally 
support publication of multicenter studies  only in their entirety and not as 
individual site data. In this case, a coordina ting investigator will be designated by 
[CONTACT_11402]. 
x Authorship will be determined by [CONTACT_14346]. 
10.2 Appendix 2: Clinical Laboratory Tests 
x The tests detailed in Table 10 –1 will be performed by [CONTACT_2237].  
x Local laboratory results are require d as outlined in the SoA (Section 1.3) or in the 
event that the central laboratory results are not available in time for either study 
intervention administration and/or response evaluation. If a local sample is 
required, it is important that the sample for central analysis is obtained at the same 
time. See Section 8.3.[ADDRESS_324870] in 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324871] be us ed. For determination of FVIII levels after 
infusion of BAY 94-9027, the use of a suitable and validated one-stage or 
chromogenic assay is crucial. 
x Protocol-specific requirements for inclusi on or exclusion of participants are 
detailed in Section 5 of the protocol. 
x Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006]. 
Table 10 –1: Protocol-required Safety Laboratory Tests 
Laboratory 
Tests Parameters 
Hematology Platelet count 
Red blood cell (RBC) count 
White blood cell (WBC) count with differential (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils) 
Hemoglobin 
Hematocrit 
Chemistry Serum: Creatinine, AST, ALT, Na, K, CO 2, Cl, BUN, total bilirubin, renal serum 
biomarkers (will include e.g., cystatin C, Lipocalin-2) 
Urine Urinary biomarkers (will include e.g., total protein, albumin, βeta-2 
microglobulin, Kidney Injury Molecule-1 (KIM-1), Lipocalin-2) 
Immunogenicity x FVIII inhibitor (see Section 8.3.9 ) 
x Anti-drug antibodies (anti-PEG antibodies and anti-PEG IgM antibodies) 
x IgE antibodies in participants with a hypersensitivity reaction 
Other tests x FVIII levels (one-stage assay at Visit 1 or chromogenic assay thereafter) 
x Quantitative PEG measurement 
x vWF (only at Visit 2, pre-infusion) 
Investigators must document their review of each laboratory safety report. 
10.3 Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow up, and Reporting 
10.3.[ADDRESS_324872] medical occurrence in a clinical study participant, 
associated with the use of study intervention, whether or not considered related to 
the study intervention. 
x NOTE: An AE can therefore be any unfavora ble and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) associated 
with the use of study intervention. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324873] results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen fro m baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying disease). 
x Exacerbation of a chronic or intermittent pre- existing condition including either 
an increase in frequency and/or intensity of the condition. 
x New conditions detected or diagnosed after study intervention administration 
even though it may have been present before the start of the study. 
x Signs, symptoms, or the clinical sequelae of a suspected intervention-
intervention interaction. 
x Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
study intervention or a concomitant medication. Overdose per se will not be 
reported as an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming intent. Such overdoses should be reported regardless of 
sequelae. 
x The signs, symptoms, and/or clinical sequelae resulting from LoE will be 
reported as an AESI (either non-serious or serious, if they fulfill the definition 
of an AE or SAE). Lack of efficacy or failure of expected pharmacological 
action also constitutes an AE or SAE. 
 
Events NOT Meeting the AE Definition  
x Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by 
[CONTACT_238533]’s condition  
x The disease/diso rder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied, unle ss more severe than expected for the 
participant’s condition  
x Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition 
that leads to the procedure is the AE 
x Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) 
x Anticipated day-to-day fluctuations of pre- existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324874] medical occurrence that, at any dose , meets the 
one or more of the criteria listed : 
a. Results in death 
b. Is life-threatening 
x The term life-threatening  in the definition of serious  refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to 
an event, which hypothetically might have caused death, if it were more severe. 
c. Requires inpatient hospi[INVESTIGATOR_178665] 
x In general, hospi[INVESTIGATOR_12994] 
(usually involving at least an overnight stay) at the hospi[INVESTIGATOR_53107]/or treatment that would not h ave been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
hospi[INVESTIGATOR_51956], the AE should be considered serious. 
x Hospi[INVESTIGATOR_5187] a pre- existing condition that did not 
worsen from baseline is not considered an AE. 
d. Results in persistent or si gnificant disability/incapacity 
x The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions. 
x This definition is not intended to include experiences of relatively minor 
medical significance such as uncom plicated headache, nausea, vomiting, 
diarrhea, influenza, and accidental trauma (e.g., sprained ankle) that may 
interfere with or prevent everyday life functions but do not constitute a 
substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Other situations: 
x Medical or scientific judgment should be exercised by [CONTACT_266950]. These events should usually be considered serious. 
x Examples of such events include invasive or malignant cancers, intensive 
treatment for allergic bronchospa sm, blood dyscrasias, convulsions, or 
development of intervention depe ndency or intervention abuse. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  55 of 69 
 
10.3.3  Recording and Follow Up of AE and/or SAE 
AE and SAE Recording  
x When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event. 
x The investigator will then record all relevant AE/SAE information. 
x It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor in lieu of completion of the CRF/ required form. 
x There may be instances when copi[INVESTIGATOR_193368]. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_266912].  
x The investigator will attempt to establish a diagnosis of the event based on 
signs, symptoms, and/or other clinical information. Whenever possible, the 
diagnosis (not the individual signs/symptoms) will be documented as the 
AE/SAE.  
Assessment of Intensity  
x The investigator will make an assessment of intensity for each AE and SAE 
reported during the study and assign it to one of the following categories:  
x Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated. 
x Moderate: Minimal, local, or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL . Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc.   
x Severe: Severe or medically signif icant but not immediately life- threatening; 
hospi[INVESTIGATOR_266913]; disabling, limiting 
self care ADL. Self care ADL refers  to bathing, dressing and undressing, 
feeding self, using the toilet, taking medications, and not bedridden.   
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  56 of 69 
 
Assessment of Causality  
x The investigator is obligated to assess the relationship between study 
intervention and each occurrence of each AE/SAE. The investigator will use 
clinical judgment to determine the relationship. 
x A reasonable possibility  of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship 
cannot be ruled out. 
x Alternative causes, such as underlying disease(s), concomitant therapy, and 
other risk factors, as well as the temporal relationship of the event to study 
intervention administration will be considered and investigated. 
x The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment. 
x For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality. 
x There ma y be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor . However, it 
is very important that the investigat or always make an assessment of 
causality for every event before the initial transmission  of the SAE data to 
the Sponsor. 
x The investigator may change his/her opi[INVESTIGATOR_9242]- up 
information and send an SAE follow-up report with the updated causality 
assessment. 
x The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow  up of AEs and SAEs 
x The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations as medically indicated or as 
requested by [CONTACT_29551]/or causality of the AE or 
SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals.  
x New or updated information will be recorded in the originally submitted 
documents. 
x The investigator will submit any updated SAE data to the Sponsor within 24 
hours of receipt of the information. 
 
10.3.4  Reporting of SAEs 
SAE Reporting to the Sponsor  via an Electronic Data Collection Tool 
x The primary mechanism for reporting an SAE to the Sponsor will be the electronic 
data collection tool.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  57 of 69 
 
x If the electronic system is unavailable, then the site will use the paper SAE data 
transmission (see next section) to report the event within 24 hours. 
x The site will enter the SAE data into the electronic system as soon as it becomes 
available. 
x After the study is completed at a given site, the electronic data collection tool will 
be taken off-line to prevent the entry of new data or changes to existing data. 
x If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously reported SAE after the electronic data collection tool 
has been taken off-line, then the site can report this information on a paper SAE 
form (see next section) or to the sponsor’s Medical Monitor  by [CONTACT_756]. 
x Contacts for SAE reporting can be found in investigator site file. 
 
SAE Reporting to the Sponsor  via Paper Data Collection Tool 
x Email transmission of the SAE paper da ta collection tool is the preferred 
method to transmit this information to the Sponsor. 
x In rare circumstances and if email transmission is not feasible , notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855]. 
x Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE data collection tool within the designated reporting 
timeframes. 
x Contacts for SAE reporting can be found in investigator site file. 
10.4 Appendix 4: AEs, SAEs, and Device Deficiencies: Definitions and 
Procedures for Recording, Evaluating, Follow up, and Reporting  
x Both the investigator and the sponsor will comply with all local reporting 
requirements for medical devices. 
x The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_324875] medical occurrence in a clinical study participant, users, or 
other persons, temporally associated with the use of study intervention, whether or 
not considered related to the medical device provided by [CONTACT_71392] S ponsor. An 
AE can th erefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of the medical device. This definition includes events related to the medical device and events related to the procedures involved. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  58 of 69 
 
10.4.2  Definition of Medical Device SAE 
A Medical Device SAE is any SAE that:  
a. Led to death  
b. Led to serious deterioration in the health of the participant, that either resulted in: 
x A life-threatening illness or injury. The term ‘life-threatening ’ in the definition of 
serious' refers to an event in which the participant was at risk of death at the time 
of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe. 
x A permanent impairment of a body structure or a body function. 
x Inpatient or prolonged hospi[INVESTIGATOR_059], planned hospi[INVESTIGATOR_272] a pre- existing 
condition, or a procedure required by [CONTACT_760], without serious deteriorat ion 
in health, is not considered an SAE. 
x Medical or surgical intervention to prevent life- threatening illness or injury or 
permanent impairment to a body structure or a body function. 
x Chronic disease (MDR 2017/745). 
c. Led to fetal distress, fetal death or a congenital abnormality or birth defect  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324876] to its 
identity, quality, durability, reliability, safety, or performance. Device 
deficiencies include malfunctions, use errors, and inadequacy of the 
information supplied by [CONTACT_3455]. 
10.4.4  Recording and Follow Up of AE/SAE/Device Deficiencies 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE/SAE/device deficiency 
reported during the study and assign it to one of the following categories:  
x Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated. 
x Moderate: Minimal, local, or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL . Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc. 
x Severe: Severe or medically signif icant but not immediately life- threatening; 
hospi[INVESTIGATOR_266913]; disabling, limiting 
self care ADL. Self care ADL refers  to bathing, dressing and undressing, 
feeding self, using the toilet, taking medications, and not bedridden.   
Assessment of Causality  
x The investigator will provide a preliminary assessment of the relationship 
between the event and the medical devices listed in Section 6.1.1 . 
Follow -up of AE/SAE/device Deficiency 
x The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations as medically indicated or as 
requested by [CONTACT_29551]/or causality of the 
AE/SAE/device deficiency as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals. 
x If a participant dies during participation in the study or during a recognized 
follow- up period, the investigator will provide the Sponsor with a copy of any 
postmortem findings including histopathology.  
x New or updated information will be recorded in the originally completed form. 
x The investigator will submit any updated SAE data to the Sponsor within 24 
hours of receipt of the information. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  60 of 69 
 
10.4.5  Reporting of AEs/SAEs Related to the Medical Devices 
x For any device related SAE:  the investigator should complete the Medical Device 
Incident form and electronically the complementary SAE page in RAVE. The 
Medical Device Incident form will be sent to the sponsor by [CONTACT_20143] 
[EMAIL_5181] within 24 hours.  
x For any AE that was assessed as device related:  the investigator should complete 
the Medical Device Incident form and elect ronically the complementary AE page in 
RAVE. The Medical Device Incident form will be sent to the sponsor by [CONTACT_20143] 
[EMAIL_5181] within 24 hours. 
If the device deficiencies could potentially lead to the death or serious deterioration 
of health (=serious injury) of the study participant or others, e.g., staff, complete the 
Medical Device Incident form only and send it to the sponsor by [CONTACT_20143] 
[EMAIL_5181]. 
For any AE or SAE that occurred with the users or other person the investigator should complete the Medical Device Incident form only and send it to the sponsor via email to [EMAIL_5181] within 24 hours. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  61 of 69 
 
10.5 Appendix 5: Abbreviations and Definitions 
10.5.[ADDRESS_324877] aspartate aminotransferase 
BLA biologic license application 
BSL baseline 
BU Bethesda Unit 
CIOMS Council for International Organizations of Medical Sciences 
CONSORT Consolidated Standards of Reporting Trials 
COX-2 cyclooxygenase-2 
CRF case report form 
CTCAE Common Terminology Criteria for Adverse Event 
CVAD central venous access device 
DREs disease-related events 
ECG electrocardiogram 
eCRF electronic case report forms 
ED exposure day 
EHL extended half-life 
ELISA enzyme-linked immunoassay 
EPD electronic patient diary 
EV extension visit 
FVIII Factor VIII 
GCP Good Clinical Practice 
Haemo-QoL Haemo-QoL Kids Short Form (8-16 years old version) 
HIPAA Health Insurance Portabilit y and Accountability Act 
IB Investigator’s Brochure  
ICF informed consent form 
ICH International Council on Harmonization 
IECs/IRB Independent Ethics Committee/ Institutional Review Board 
IgE immunoglobulin E 
IgM immunoglobulin M 
IP in-person visit 
ITT intent-to-treat 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  62 of 69 
 
IU International Units 
IV intravenous 
IxRS interactive voice/web randomization system 
LoE loss of efficacy 
MAA marketing authorization application 
mITT modified intent-to-treat 
mSAF modified Safety analysis set 
PEG polyethylene glycol 
PK Pharmacokinetics 
PMS post-marketing surveillance 
PROs patient-reported outcomes 
PTC product technical complaint 
PTPs previously treated patients 
PUPs previously untreated patients 
QoL Quality of Life 
RBC red blood cell 
rFVIII recombinant FVIII 
SAE serious adverse event 
SAF safety analysis set 
SCR screening 
SDLL Source Data Location List 
SHL standard half-life 
SmPC Summary of Product Characteristics 
SoA Schedule of Activities 
S[LOCATION_003]Rs suspected unexpected serious adverse reactions 
USPI [INVESTIGATOR_266914] 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  63 of 69 
 
10.5.2  Definitions 
Term Definition 
Study intervention BAY 94-9027 
Legal guardian Parent(s) (preferably both if available or as per local requirements), legally 
appointed guardian(s), or legally acceptable representative(s), as defined by 
[CONTACT_266951], who consent(s) on behalf of the minor. 
For the purposes of  this study, all references to informed consent and assent 
refer to the pediatric participant (child) and his or her legal guardian who have provided consent (and assent as applicable) according to the Informed Consent Process and Assent Form described in 
Section 10.1.3  Informed 
Consent and Assent Process 
Caregiver Delegated primary caregiver(s) who will be responsible for ensuring the study 
activities are conducted per protocol, e.g., accompany the participant to the 
study site on each assessment day according to the S oA; consistently and 
consecutively be available to provide information on the participant using the 
rating scales during the scheduled study visits; ac curately and reliably 
dispense study intervention as directed; help the study  site personnel ensure 
follow  up. This person may be the legal guardian, or another appropriate 
person, delegated by [CONTACT_266952] A younger than 18 years of age participating in 
research study 
 
10.6 Appendix 6: Protocol Amendment History 
The Protocol Amendment Summary of Changes Ta ble for the current amendment is located 
directly before the table of contents. 
Amendment 1: 25 MAY 2022 This amendment is considered to be substantial ba sed on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliame nt and the Council of the European Union. 
Overall Rationale for the Amendment The amendment introduces an additional year of prophylactic treatment with Jivi® 
culminating in a total of 2 years treatment duration in children of 7-<[ADDRESS_324878] KIDS (study [ZIP_CODE]; NCT0 1775618) and support label extension in the 
pertaining age group.  
Furthermore, the treatment prolongation offers sustained study drug provision for 2 years and 
avoid unnecessary switches of responder patients to other approved FVIII products. 
Section #  
and Name [CONTACT_266958]. Substance name [CONTACT_266959]. 
Acronym added. Current study acronym was not in use at 
the time of the original protocol. 
Registry ID removed. Text was erroneously included in the 
original protocol. 
Name [CONTACT_266960]. Changed to reflect current team 
responsibilities. 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324879] 
of objectives and endpoints is available in 
Section 3. 
Duration of extension 
study (Part B) described 
in the short summary increased from [ADDRESS_324880] change in duration for the extension study (Part B) from 6 to 18 
months.  Change reflects treatment prolongation.  
1.3 Schedule of Activities 
(SoA)  Schedule of assessment 
for Part A (Table 1 -1) 
revised to include PEG 
quantification, Urine / serum biomarkers for renal safety, and neurological assessment at Visit 2 and Visit 11. 
Footnote added for each 
of these assessments at Visit 2 added stating that the assessments can be performed at a visit other 
than ba
seline if the 
participant is enrolled 
before Amendment 1 is implemented. Added PEG-related safety assessments 
specifically associated with the long -term 
use of pegylated FVIII products.  
Footnote added to 
Schedule of assessment for Part A (Table 1
-1) 
clarifying procedures for 
the early discontinuation 
visit for participants with adverse events of special interest (AESI).  In-hospi[INVESTIGATOR_266915] (hypersensitivity or loss of 
efficacy). 
Return used /unused 
study intervention at Visit Visit 6 can be an in-person visit or a 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  65 of 69 
 
6 removed from 
Schedule of assessment for Part A (Table 1
-1). phone call, therefore  
participants were provided with a study intervention supply sufficient 
to last 
through Visit 7.  Participants who attend 
an in -person visit for Visit 6 should return 
study intervention at Visit 7. 
Footnote added to 
Schedule of assessment 
for Part A (Table 1 -1) 
and Part B (Table 1 -2) 
with a cross -reference to 
Section 10.2. Cross-reference added to direct to full 
details on clinical laboratory parameters. 
Schedule of assessment 
for Part B (Table 1 -2) 
revised to reflect 
increase in duration from 6 months to 18 months. Monthly visits for Months 13 – 24 added.  Change reflects increase in duration. 
Schedule of assessment 
for Part B (Table 1 -2) 
revised to include PEG 
quantification, Urine / serum biomarkers for renal safety, and neurological assessment at Visit 18. Added PEG-related safety assessments 
specifically associated wi th the long- term 
use of pegylated FVIII products  
Footnotes in Schedule of 
assessment for Part A 
(Table 1 -1) and Part B 
(Table 1-2) relabeled. Footnote labels revised to reflect 
additions and revisions to original 
schedules of assessments  
2.[ADDRESS_324881] 
addition of long -term 
safety assessments. Study prolongation will allow generation 
of long -term safety data.  
2.3.1 Risk Assessment  Text regarding potential 
class risk of pegylated FVIII replacement 
products and previous 
experience with Jivi
® 
added.  Potential class risk for pegylated FVIII 
replacement products following long -term 
treatment added as determined by [CONTACT_16096]. 
From Jivi’s preclinical and long -term 
clinical program no PEG -related safety 
observations associated with long- term 
use of J ivi were reported.  
[ADDRESS_324882] prolongation of study 
duration and addition of long -term safety-
related measurements.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324883] prolongation of study 
duration.  
4.1 Overall Design Duration of extension 
study (Part B) increased from 6 months to 18 months. Study prolongation will provide treatment 
to patients for 2 years and avoid unnecessary switches of responder patients to other ap proved FVIII products. 
5.1 Inclusion Criteria Inclusion criterion 2 
reworded to clarify that 
FVIII activity does not 
need to be measured at the time of screening if the participant has reliable prior 
documentation in clinical 
records. Original text was not clear resulting in 
misunderstandings at study sites.  
6.2 Preparation, Handling, 
Storage, and Accountability
 Wording describing 
provision of instructions for use corrected.
 The original wording stating that 
participants would be provided with the Jivi
® prescribing information was 
incorrect. Participants are provided with 
instructions for preparation of study 
intervention, which is ba sed on the 
prescribing information. 
6.8 Concomitant Therapy Vaccination history 
revised from complete vaccination history to history of vaccinations received within 2 years of enrollment (including 
vaccination for COVID-
19).
 The history of vaccination has been 
shortened to the last [ADDRESS_324884] any hypersensitivity (HS) reactions that may have occurred close to the time of enrollment in the study.
 
  
History of COVID -[ADDRESS_324885] of safety assessments.
 
8.2.1 Physical 
Examination Neurological assessment 
added to the description Neurological assessment added as part 
of the PEG-related safety assessments 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  67 of 69 
 
of physical examinations 
perfo rmed during the 
study. to investigate the potential long-term 
Jivi® safety. 
8.3.[ADDRESS_324886] (AESI) Description of number of 
blood samples for AESIs correc
ted. One blood/plasma sample is sufficient to 
measure anti -PEG, anti- PEG IgM, and 
IgE. Original wording described collection of a distinct sample for measurement of 
IgE. 
 Description for the 
follow -up (early 
discontinuation) visit for 
AESI events revised for clarity. Wording for assessments performed 
at this visit changed to 
emphasize measurement of FVIII inhibitor and anti-PEG IgM at this visit and clarify that factor VIII recovery and in
-hospi[INVESTIGATOR_266916]. Language added to clarify that the follow-
up visit [ADDRESS_324887] 6 months of Part 
B has not been changed; therefore, the 
Month 6 analysis has been added in addition to the analysis at the end of the study. 
10.2 Appendix 2: Clinical 
Laboratory Tests  Serum chemistry 
parameters added. Added PEG-related safety assessments 
specifically associated with the long -term 
use of pegylated FVIII products  Urinary parameters 
added. 
For other tests, 
quantitative PEG 
measurement and  vWF 
added. Text describing measurement of FVIII revised to clarify that a one
-stage assay is used 
only at Visit 1.  
10.4.5 Reporting of 
AEs/SAEs related to the 
Medical Devices  Removed all instances of 
the word “manually” from 
instructions for 
completion  of the 
Medical Device Incident 
form. Medical Device Incident form is 
completed electronically. Original 
language was causing 
misunderstandings at study sites.  
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  [ADDRESS_324888] been made throughout the document. These minor changes are not 
individually summarized. 
 
CONFIDENTIAL Clinical Study Protocol Amendment 2 (Global) 
No. BAY 94-9027 / [ZIP_CODE] 
06 APR 2023  Page:  69 of 69 
 
11. References  
Baumann A, Pi[CONTACT_139020] I, Hucke F, Sandmann S, Hetzel T, Schwarz T. Pharmacokinetics, excretion, 
distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. Eur J Pharm Sci. 2019 Mar 15;130:11-20. 
Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-
9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96. 
EMA. Committee for Medicinal Products for Human Use (CHMP). Safety Working Party’s 
response to the PDCO regarding the use of PEGylated drug products in the paediatric population. . EMA/CHMP/SWP/647258/2012. 2012 16 November:1-3. 
Franchini M, Coppola A, Rocino A, Santagostino E, Tagliaferri A, Zanon E, et al. Systematic 
review of the role of FVIII concentrates in inhibitor development in previously 
untreated patients with severe hemophi lia a: a [ADDRESS_324889];39(7):752-66. 
JIVI SmPC. Summary of Product Characteristics (EU). Available on: 
https://www.ema.europa.eu/en/documen ts/product-information/jivi-epar-product-
information_en.pdf. 2018. 
JIVI® Prescribing information. lyophilized powder for solution, for intravenous use Initial 
U.S. Available on: https://labeling.baye rhealthcare.com/html/products/pi/Jivi_PI.pdf. 
2018. 
Mancuso ME, Biss T, Fischer K, Maas Enriquez M, Steele M, Wang M, et al. PROTECT 
VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with  severe haemophilia A. Haemophilia. 2021 
May;27(3):434-44. 
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A 
Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2054-64. 
Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, et al. Safety and efficacy of 
BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017 Mar;15(3):411-9. 
Reding MT, Pabinger I, Holme PA, Poulsen L, Negrier C, Chalasani P, et al. Confirmed long-
term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe 
haemophilia A: final results of the PROTEC T VIII extension study. Haemophilia. 
2021 May;27(3):e347-e56. 
Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M. PROTECT VIII Kids: BAY 
94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophili a A. Haemophilia. 2020 May;26(3):e55-e65. 
Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, et al. BAY 94-9027, a 
PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies. Haemophilia. 2018 Sep;24(5):733-
40. 
Srivastava A, Santagostino E, Dougall A, Kitc hen S, Sutherland M, Pi[INVESTIGATOR_266917], et al. WFH 
Guidelines for the Management of Hem ophilia, 3rd edition. Haemophilia. 2020 Aug 
3:1-158. 
 